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ABSTRACT
Diabetes is a chronic metabolic disease that leads to vasculopathy involving
the small and large blood vessels. Studies on animal models indicate that,
GLP-1 analogues might have beneficial effects on the above mentioned
complications over and above the improvements due to glycaemic control. The
aims of this study were to explore effects of the GLP-1 analogue, liraglutide
on the microvascular complications and cardiovascular risk in human subjects
with diabetes.
In a retrospective cohort study, I compared a group of patients who received
liraglutide with a matched group of subjects with type 2 diabetes on other
treatments. The changes in urinary albumin:creatinine ratios and retinopathy
grades of these patients were compared after 12 months. In a prospective
study, the serum biomarkers of diabetic nephropathy and diabetic retinopathy
were measured in a group of subjects with type 2 diabetes, before and 3
months after treatment with liraglutide. In addition body composition analysis
of a group of morbidly obese patients with type 2 diabetes was performed
before, and 3 months after treatment with liraglutide.
In subjects with established microalbuminuria, treatment with liraglutide for
12 months did not have any effect on albumin excretion rate. Similarly, no
changes in urinary albumin:creatinine ratios were evident in
normoalbuminuric subjects after 12 months of treatment with liraglutide. I did
not find any significant changes in the biomarkers of diabetic nephropathy
following treatment with liraglutide.
In patients with type 2 diabetes, therapy with liraglutide for 12 months did not
influence the course of diabetic retinopathy. No changes in the serum
concentrations of VEGF (which is a biomarker for retinopathy) were noted in
patients after treatment with liraglutide.
In morbidly obese subjects with type 2 diabetes, 3 months of treatment with
liraglutide induced significant improvements in the markers of cardiovascular
risk and reduced total body fat mass. An improvement in the mean insulin
sensitivity was noted after treatment; however this did not reach statistical
significance.
In conclusion, my study has shown that treatment of patients with type 2
diabetes and obesity with liraglutide was associated with improvements in
markers of cardiovascular risk; but no changes in diabetic renal disease or
diabetic retinopathy were evident.
20
CHAPTER 1
GENERAL INTRODUCTION
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Diabetes Mellitus
Prevalence and classification of diabetes
Diabetes mellitus is the most common chronic metabolic disease, and its
prevalence continues to increase (Shaw, Sicree et al. 2010, Danaei, Finucane et
al. 2011). The increasing global prevalence of obesity is closely associated
with the increase in incidence of type 2 diabetes (Vinciguerra, Baratta et al.
2013). It is estimated that there were 285 million people with diabetes
worldwide in 2010. This number is projected to increase to increase by 54% by
2030, fuelled by population growth, ageing of populations, urbanisation and
associated lifestyle changes (Ramachandran, Snehalatha et al. 1999). There is
accumulating evidence that specific lifestyle intervention programs reduce the
incidence of type 2 diabetes (Pan, Li et al. 1997, Ramachandran, Snehalatha et
al. 2006).
Diabetes mellitus needs on going medical care and self-management by
patients. The management is often complex especially in the later stages of the
disease and needs to address a number of other medical problems in addition
to glycaemic control. Diabetes is classified as (2012)
1. Type1 diabetes due to β cell destruction leading to absolute insulin 
deficiency
2. Type 2 diabetes due to a combination of insulin resistance and relative
insulin deficiency
3. Other specific types of diabetes due to genetic syndromes, drugs and
diseases of the exocrine pancreas
4. Gestational diabetes which is first diagnosed during pregnancy
22
In some patients it might be difficult to distinguish between type 1 and type 2
diabetes at the time of initial presentation. The diagnosis may become more
obvious with time.
Management of diabetes
Patients with diabetes should be managed by multidisciplinary teams including
physicians, diabetes nurses, dieticians, podiatrists and pharmacists. The input
from other health professionals may be required in different stages of the
disease. In addition, it is vital that patients with diabetes take an active part in
self-management (2012). Initial management of diabetes includes appropriate
diet, exercise and a healthy life style (National Collaborating Centre for
Chronic 2008). Insulin is the mainstay of treatment for glycaemic control in
patients with type 1 diabetes and some patients with other specific types of
diabetes. A number of other oral and parenteral drugs may be considered for
patients with type 2 diabetes.
Economic burden of diabetes
The estimated total cost of diabetes in the United States of America in 2002
was $132 billion, which increased to $174 billion in 2007 (Hogan, Dall et al.
2003, Association 2008). By 2012 this figure increased to $245 billion,
confirming the continued upward trend in the economic burden of the disease
(Association 2013). People with diabetes are more likely to require hospital
inpatient care, multiple medications, outpatient visits to physicians and other
health professionals. Patients with diabetes are more likely to be admitted to
the hospital with other medical problems and are have higher average lengths
23
of stay in hospital (Association 2008). A substantial amount of attributed
health resource use is for the chronic complications of diabetes, especially
complications related to macrovascular disease and diabetic nephropathy
(Association 2013). Estimates from countries in Asia and Europe confirm the
increasing economic costs of diabetes and the consequent strain on health
resources (Ballesta, Carral et al. 2006, Chatterjee, Riewpaiboon et al. 2011,
Marchesini, Forlani et al. 2011).
Complications of diabetes
Diabetes may be regarded primarily as a vascular disease that manifests as
hyperglycaemia (Aiello, Gardner et al. 1998). The chronic complications of
diabetes are broadly classified into microvascular and macrovascular. The
clinical manifestations of macrovascular disease include coronary artery
disease, cerebrovascular disease and peripheral vascular disease (1998).
Indeed a major share of mortality due to diabetes is attributed to
macrovascular disease (Association 2008). The clinical presentations of
microvascular disease include nephropathy, retinopathy and neuropathy that
are associated with significant morbidity due to diabetes (Brinchmann-Hansen,
Dahl-Jørgensen et al. 1992).
24
Figure 1.1: CARTOON DEPICTING THE MAJOR CHRONIC
COMPLICATIONS OF DIABETES. The microvascular complications nvolve
the kidneys, retinae and nerves. The macro vascular complications are
manifested as heart attack, stroke or peripheral vascular disease.
25
Diabetic nephropathy
Overview of diabetic nephropathy
Diabetic nephropathy is a major cause of chronic kidney disease, and currently
the most common cause of end stage renal failure (Molitch, DeFronzo et al.
2004). Management of patients with chronic kidney disease and diabetes is
more complex and expensive than management of patients with diabetes alone
(Laliberté, Bookhart et al. 2009). Glomerular hyperperfusion and
hyperfiltration herald the onset of nephropathy, followed by leakage of
albumin in urine, and subsequently progressive renal failure (Molitch,
DeFronzo et al. 2004). Albuminuria is an indicator of renal pathology and also
an independent marker of cardiovascular risk (Mann, Yi et al. 2004). There is a
further increase in the cardiovascular risk of patients with diabetes that mirrors
a decline in the glomerular filtration rate (Ninomiya, Perkovic et al. 2009).
About a third of patients with diabetes develop significant nephropathy, and
the associated pathologic changes in the kidneys of these patients are complex
and heterogeneous (Gambara, Mecca et al. 1993). Poorly controlled diabetes,
hypertension and genetic predisposition are associated with progressive renal
disease due to diabetic nephropathy (Dronavalli, Duka et al. 2008).
Screening and diagnosis of diabetic nephropathy
As early stages of diabetes related renal damage are completely asymptomatic,
it is recommended that all patients with diabetes are screened annually for
urinary albumin excretion in addition to serum creatinine (Rodbard, Blonde et
al. 2007). Microalbuminuria is the earliest indicator of renal involvement and
has been traditionally defined as 30-300 mg of albumin in a 24 hour collection
26
of urine. Although a 24 hour collection of urine would be ideal in order to
account for diurnal variations in albumin excretion, it is often impractical in a
clinical setting (2012). The ratio of albumin to creatinine in a spot sample of
urine gives comparable results to total albumin excretion in a 24 hour
collection (Bakker 1999). Urinary albumin:creatinine ratio in spot urine
samples more than 2.5 mg/mmol in men or 3.5 mg/mmol in women are
diagnostic of microalbuminuria (National Collaborating Centre for Chronic
2008).
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Figure 1.2: CARTOON DEPICTING ALBUMIN LEAKAGE FROM THE
GLOMERULUS. It has been postulated that the integrity of the glomerular
basement membrane is breached in diabetic nephropathy allowing leakage of
large proteins form the plasma into the renal tubules.
28
Management of diabetic nephropathy
Glycaemic control
The UK prospective diabetes study is one of the largest clinical studies
conducted on patients with type 2 diabetes. Appropriately matched cases and
controls were randomised to either tight glycaemic control (HbA1c of 7%) or
usual treatment (HbA1c of 7.9%). After 9 years there was a significant
reduction in the relative risk of microalbuminuria ( 0.76, 99% confidence
interval 0.62-0.91, p<0.001) and the relative risk of doubling of serum
creatinine ( 0.40, 99% confidence interval 0.14-1.20, p=0..27) in the group of
patients on the tight glycaemic control arm (1998). Early and intensive
glycaemic control was associated with a 24% relative risk reduction in the
long term risk of composite microvascular end points including diabetic
nephropathy (Holman, Paul et al. 2008).
These observations were confirmed in the diabetes control and complications
trial (DCCT), which had a similar design, but involved patients with type 1
diabetes (2000). Intensive glycaemic control was associated with a 39%
reduction (95% confidence interval 21%-52%) in microalbuminuria and a 54%
reduction in albuminuria (95% confidence interval 19%-74%). Hence it is
recommended that patients with diabetes are treated with lifestyle measures
and appropriate drugs aiming for HbA1c of 7% or less without inducing
hypoglycaemic episodes (2012).
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Management of blood pressure
Appropriate anti-hypertensive treatment is an important aspect of the overall
management of patients with incipient and established diabetic nephropathy
(Cooper 1998). It has been shown that stabilization of urinary albumin
excretion and attenuation of decline in glomerular filtration rate (GFR)
correlate with the mean arterial pressure (Jerums, Allen et al. 2004). In one
arm of the UKPDS study, patients were randomized to tight blood pressure
control (144/82 mm Hg) or normal treatment (154/87). A clinically important
reduction in the urinary albumin excretion was seen in the tight blood pressure
control group (1998).
Inhibition of the renin-angiotensin-aldosterone axis might favourably influence
the glomerular haemodynamics in patients with diabetes (Lewis, Hunsicker et
al. 1993). Angiotensin-2 has been shown to exert a tonic constrictive effect on
the efferent arteriole, thereby increasing the intraglomerular pressure and
leading on to leak of albumin in the urine. Indeed inhibitors of the angiotensin
convertase enzyme and blockers of the angiotensin receptor are effective in
slowing the progression of microalbuminuria (Lewis, Hunsicker et al. 1993,
Brenner, Cooper et al. 2001, Chan, Wat et al. 2004). A recent systematic
review concluded that most of the renoprotective effect of these classes of
drugs is due to the reduction in blood pressure (Casas, Chua et al. 2005).
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Recent advances in pathogenesis
Inflammation in nephropathy
Diabetic nephropathy has been traditionally considered as a non-inflammatory
condition, but recent studies have identified inflammation as a key component
in the initiation and progression of its pathology. Macrophage activation is a
key event in experimental models of diabetes and in human subjects (Chow,
Ozols et al. 2004). This is associated with glomerular immune complex
deposition, chemokine production, progressive fibrosis, eventually leading to
glomerular sclerosis (Furuta, Saito et al. 1993, Galkina and Ley 2006).
Conversely, experimental studies impairing leucocyte recruitment in the
kidney have shown a reduction in albuminuria, in addition to a reduction in
glomerular and tubulointerstitial injury (Chow, Nikolic-Paterson et al. 2005).
Accumulation of T-lymphocytes in the kidney has been noted in human
subjects with type 1 diabetes and early diabetic nephropathy (Moriya, Manivel
et al. 2004). Advanced glycation end products bind to specific receptors on
lymphocytes, inducing production of interferons and recruitment of
macrophages (Imani, Horii et al. 1993). A number of inflammatory cytokines
produced by endothelial cells and leucocytes are implicated in the
pathogenesis of nephropathy (Lim and Tesch 2012)
Endothelium in the kidney
The endothelium lines the entire circulatory system and covers up to 7000 m2
of surface area, making it one of the largest organs in the human body. The
physiologic functions of the endothelium differ in different organ systems(Aird
2003). The kidneys receive about 25% of the cardiac output at rest via the
main renal arteries, which divide into segmental arteries and later into arcuate
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arteries, interlobular arteries and finally to afferent arterioles. The glomerular
capillaries receive blood from the afferent arterioles. Ultrafiltration of plasma
occurs in the glomerulus through the fenestrations in the capillary endothelial
cells(Brodsky and Goligorsky 2012). As in other tissues, endothelium in the
kidney is located in close proximity to and in constant dialogue with other cell
types (Thomas, Witting et al. 2008). Endothelial dysfunction, especially in the
glomerulus is an important step in the early pathogenesis of diabetes related
renal injury (Nakagawa, Segal et al. 2007, Ziyadeh and Wolf 2008). Blood
levels of soluble Intercellular Adhesion Molecule-1 (sICAM-1) and soluble
Vascular Cell Adhesion Molecule-1 (sVCAM-1) are well validated biomarkers
of endothelial dysfunction (Gearing, Hemingway et al. 1992, Witkowska and
Borawska 2004).
Biomarkers of diabetic nephropathy
sICAM-1
ICAM-1 consists of five extracellular domains and is expressed on the surface
of endothelial cells (Rothlein, Mainolfi et al. 1991, Fonsatti, Lamaj et al.
1999). The sICAM-1 in blood represents a circulating form of the protein and
reflects the degree of expression of ICAM-1 on the cell surface(Leeuwenberg,
Smeets et al. 1992). The release of sICAM-1 is induced by pro inflammatory
cytokines such as Tumour Necrosis Factor-α (TNF-α), Interlukin-1 (IL-1) and 
Interlukin-6 (IL-6), whereas it is inhibited by Interlukin-10 (IL-10), insulin and
antioxidants(Witkowska and Borawska 2004). In vitro studies suggest that
ICAM-1 might promote angiogenesis by stimulating endothelial cell migration
and endothelial cell tube formation(Gho, Kleinman et al. 1999).
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sICAM-1 in diabetic nephropathy
In an experimental study, sICAM-1 intact and deficient db/db mice with
equivalent hyperglycaemia and obesity were compared for renal end points.
The sICAM-1 deficient mice had a 77% reduction in albuminuria at 6 months.
In addition these mice had significant reductions in glomerular leucocyte
infiltration which was associated with reduced glomerular hypertrophy(Chow,
Nikolic-Paterson et al. 2005). When diabetes was induced by streptozocin in
sICAM-1 intact and deficient mice, glomerular hypertrophy and mesangial
matrix expansion were significantly lower in the latter group of mice. The
sICAM-1 deficient mice expressed lower levels of Transforming Growth
Factor-β (TGF-β) and type-4 collagen in their glomeruli(Okada, Shikata et al. 
2003). Wistar fatty, a genetically obese rat strain is an animal model for type 2
diabetes. sICAM-1 was expressed on the glomeruli of the rats and the
expression was associated with development of nephropathy(Matsui, Suzuki et
al. 1996). These studies indicate that sICAM-1 is critically involved in the
pathogenesis of diabetes related renal disease.
sVCAM-1
VCAM-1 is present in plasma as a soluble form, sVCAM-1(Arora, Gunther et
al. 2010). The plasma sVCAM-1 is a useful biomarker of endothelial stress
because, its levels increase with activation of endothelium (Gearing,
Hemingway et al. 1992, Pizzolo, Vinante et al. 1994). VCAM-1 is a member
of the immunoglobulin family of proteins and exists in two forms in humans
(Cybulsky, Fries et al. 1991). VCAM-1 expression in endothelial cells can be
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induced mechanically by turbulent blood flow or by the effect of inflammatory
cytokines (Carluccio, Ancora et al. 2007). VCAM-1 functions as a scaffolding
for leucocyte migration and as a signalling mediator through generation of
reactive oxygen species(Cook-Mills, Marchese et al. 2011).
sVCAM-1 in diabetic nephropathy
There is evidence from animal and human studies suggest that sVCAM-1 is
involved in the pathogenesis of diabetic nephropathy. In an experimental study
on spontaneously diabetic KKAy mice, the expression of sVCAM-1 in the
kidney was assessed after development of albuminuria. The renal interstitium
was infiltrated by monocytes, lymphocytes and plasma cells indicating on
going inflammation associated with diabetic renal disease. There was
increased expression of sVCAM-1 by the infiltrating cells and endothelial cells
of venules, suggesting that sVCAM-1 expression contributes to the interstitial
inflammation(Ina, Kitamura et al. 1999). Treatment of diabetic rats with
experimental anti-inflammatory agents resulted in an inhibition of diabetes
induced hypertrophy of the glomeruli. This was associated with a decrease in
the expression of pro-inflammatory factors such as sVCAM-1, sICAM-1 and
MCP-1 in the renal tissue, suggesting that these molecules are involved in the
inflammatory process(Wang, Li et al. 2008).
In a cross sectional study involving 95 human subjects with type 2 diabetes,
circulating sVCAM-1 levels were correlated with markers of microvascular
(nephropathy, retinopathy and neuropathy) disease. On multivariate regression
analysis, only diabetic nephropathy was associated with serum sVCAM-1
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concentration. The sVCAM-1 levels correlated with urinary albumin excretion
in patients with normal serum creatinine (Koga, Otsuki et al. 1998). It has been
noted that sVCAM-1 levels are higher in albuminuric patients with type 2
diabetes when compared with matched group of subjects with normal urinary
albumin excretion (Murakami, Tamasawa et al. 2001, Rubio-Guerra, Vargas-
Robles et al. 2007).
Monocyte Chemo attractant Protein -1 (MCP-1)
Chemokines constitute a family of chemo attractant cytokines that play a
major role in selectively recruiting monocytes, neutrophils, and lymphocytes,
as well as in inducing chemotaxis (Deshmane, Kremlev et al. 2009). MCP-1 is
one of the key chemokines that regulates migration and infiltration of
monocytes/macrophages (Cochran, Reffel et al. 1983). Monocyte migration
across the endothelium is required for immunological surveillance and for
mounting an inflammatory response. MCP-1 is produced by many cell types,
including endothelial cells, fibroblasts, epithelial cells, smooth muscle,
mesangial cells, astrocytes, monocytes, and microglial cells. But the major
source of MCP-1 are monocyte/macrophages (Cushing, Berliner et al. 1990,
Standiford, Kunkel et al. 1991, Brown, Strieter et al. 1992). MCP-1 has been
shown to be a potential intervention point for the treatment of various
autoimmune diseases, including multiple sclerosis (Sørensen, Ransohoff et al.
2004), rheumatoid arthritis (Hayashida, Nanki et al. 2001) and
diabetes(Sartipy and Loskutoff 2003).
35
Diabetic nephropathy in MCP-1 knockout mouse models
Diabetic nephropathy involves a renal inflammatory response mediated by
macrophages that accumulate in kidneys in association with the local up
regulation of monocyte MCP-1. A study examined the progression of
streptozocin induced diabetic nephropathy in mice with deficiency of MCP-1.
Renal pathology was examined at 2, 8, 12 and 18 weeks after STZ treatment in
MCP-1 intact (+/+) and deficient (-/-) mice. Diabetes of 18 weeks duration
resulted in albuminuria and renal failure in MCP-1(+/+) mice, but MCP-1(-/-)
mice were largely free of these aspects of renal injury. This suggests that
MCP-1-mediated macrophage accumulation and activation plays a critical role
in the development of diabetic nephropathy in a mouse model(Chow, Nikolic-
Paterson et al. 2006).
Another study explored the role of MCP-1 in the progression of renal injury in
obese db/db mice that were deficient in the gene encoding MCP-1. The
incidence and development of type 2 diabetes were similar in MCP-1(+/+) and
MCP-1(-/-) db/db mice between 8 and 32 weeks of age. However, kidney
macrophage accumulation and the progression of albuminuria and renal
fibrosis were substantially reduced in MCP-1(-/-) mice when compared with
MCP-1(+/+) db/db mice. Hence, MCP-1 plays a critical role in inflammation
of the kidney, during the course of type 2 diabetes(Chow, Nikolic-Paterson et
al. 2007).
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Role of MCP-1 antagonists in mouse models of diabetic nephropathy
In a mouse model of diabetic nephropathy, the role of MCP-1 antagonist
treatment was assessed by blocking its downstream mediators. In this study,
meningeal matrix expansion, type IV collagen, transforming growth factor-
beta1 positive area, and macrophage infiltration in glomeruli were measured at
baseline and after 12 weeks. It was shown that blocking the MCP-1 pathway
ameliorated glomerulosclerosis, indicating that the pathway plays a crucial
role in the progression of diabetic nephropathy(Kanamori, Matsubara et al.
2007). In another study, MCP-1 was blocked by mNOX-E36-3'PEG which is
an anti-Ccl2 L-enantiomeric RNA aptamer that binds with murine MCP-1 and
blocks the recruitment of macrophages to the kidneys of db/db mice with type
2 diabetes. The antagonist was injected subcutaneously three times per week
into db/db mice with advanced glomerulopathy from 4 to 6 months of age. It
was noted that mNOX-E36-3'PEG reduced the number of glomerular
macrophages by 40% compared with control db/db mice. This was associated
with protection from diffuse glomerulosclerosis and significantly improved the
glomerular filtration rate suggesting a key role for MCP-1 in mediating
progression of nephropathy (Ninichuk, Clauss et al. 2008).
High sensitivity C-reactive protein (hsCRP)
C-reactive protein is produced in the liver during acute and chronic
inflammatory processes (Szalai and McCrory 2002). Its levels can rise up to a
thousand fold in 48 hours following a sufficiently large inflammatory insult
(Gabay and Kushner 1999). C-reactive protein has a potential anti-microbial
role by virtue of its ability to bind to the bacterial cell wall (Abernethy and
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Avery 1941). Recently it has been recognised that CRP is a useful marker of
low grade inflammation associated with a number of vascular diseases (Libby,
Ridker et al. 2002). Indeed, there is some evidence that CRP might activate
endothelial cells to induce production of adhesion molecules and chemotactic
factors (Pasceri, Willerson et al. 2000, Pasceri, Cheng et al. 2001). It has been
shown that within person variability of high sensitivity CRP is low. Hence it is
a biologically stable marker of vascular dysfunction, providing that the patient
is not having an active infection or taking medications that might affect
inflammatory responses (Ridker, Rifai et al. 1999).
Diabetic retinopathy
Overview of diabetic retinopathy
Diabetic retinopathy is the most frequent cause of blindness in adults (Aiello,
Gardner et al. 1998). Twenty years after diagnosis, nearly all patients with type
1 diabetes and at least 60% of patients with type 2 diabetes will have evidence
of retinopathy (Fong, Aiello et al. 2004). Diabetic retinopathy with visual loss
has a profound negative impact on the lives of patients (Coyne, Margolis et al.
2004). Studies have shown that diabetic retinopathy with mild or negligible
visual impairment is also associated with poor quality of life (Klein, Moss et
al. 2001).
The early stages of retinopathy are characterised by increased vascular
permeability that progresses to ischemia and neovascularisation of retinal
microvasculature (Fong, Aiello et al. 2004). Clinically retinopathy progresses
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from background changes leading to pre-proliferative stage and eventually to
proliferative retinopathy.
Screening for diabetic retinopathy
The NHS diabetic eye screening program in the UK systematically screens all
patients over the age of 12 in the country with diabetes (Scanlon 2008). About
80 local screening programs deliver screening across England coordinated and
led by the screening program centre in Gloucester. In 2008, it was estimated
that there were two million people with diabetes over the age of 12 and an
annual incidence of blindness of 1280 among this population (Scanlon 2008).
Screening is performed by digital retinal photography, which is graded by
appropriately trained graders. Retinopathy is graded into four levels: none
(R0), background retinopathy (R1), pre-proliferative retinopathy (R2) and
proliferative retinopathy (R3). Maculopathy is graded as absent (M0) or
present (M1). Similarly, previous photocoagulation is graded as absent (P0) or
present (P1). The presence of sight threatening maculopathy, pre-proliferative
retinopathy or worse is considered as sight threatening diabetic retinopathy
(Harding, Greenwood et al. 2003). After grading patients are referred for
appropriate treatment if required, according to agreed pathways (Leese, Morris
et al. 2005).
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Figure 1.3: RETINAL PHOTOGRAPHS SHOWING NORMAL RETINA
AND RETINA WITH DIABETIC RETINOPATHY
Management of diabetic retinopathy
Management of glycaemia and hypertension
In the DCCT trial 1441 patients with type 1 diabetes, who either had no
retinopathy or minimal to moderate non-proliferative retinopathy, were
randomised to receive conventional or intensive treatment (1993). Intensive
therapy slowed the onset of retinopathy by 76% (95% confidence interval, 62-
85%) and progression of retinopathy by 54% (95% confidence interval, 39-
66%) (Nathan, Zinman et al. 2009). The protective effect of glycaemic control
on retinopathy has also been confirmed for patient with type 2 diabetes. In the
UKPDS trial, a continuous relationship was noted between glycaemia and
microvascular complications. For every percentage point reduction in HbA1c,
there was a 35% relative risk reduction in microvascular complications (Fong,
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Aiello et al. 2004). Hence tight glycaemic control, with avoidance of
hypoglycaemia is an integral part of management of diabetic retinopathy.
Long term follow up data from participants in the UKPDS trial suggests that
hypertension is closely linked to the progression of retinopathy (Matthews,
Stratton et al. 2004). The relative risk of deterioration in the retinopathy
scores of 2 or more (on the ETDRS scale) was lower (0.75, p=0.02) in patients
who had tight blood pressure control. In addition, the absolute incidence of
blindness in one eye was 3.1/1000 patient years in the tight blood pressure
group, versus 4.1/1000 patient years in the conventional blood pressure
treatment group (p=0.046, Relative risk 0.76; 99% confidence interval 0.29-
1.99). In addition to glycaemic control, treatment of blood pressure is a vital
component of management of diabetic retinopathy.
Laser photocoagulation
Pan retinal laser photocoagulation is an established treatment for the
management of non-proliferative and proliferative diabetic retinopathy (Frank
2004). The diabetic retinopathy study (DRS) randomised patients with
bilateral non-proliferative retinopathy or proliferative retinopathy in at least
one eye to receive pan-retinal photocoagulation or no treatment (1981). After 2
years there was a significant reduction in the rate of severe visual loss in the
treated eyes. The greatest benefits (up to a 50% reduction in relative risk of
severe visual loss) were seen in eyes with high risk characteristics. The early
treatment in diabetic retinopathy study randomised patients with less severe
diabetic retinopathy and visual acuity greater than 20/100 to early laser therapy
or deferred treatment (1991). Early photocoagulation reduced the relative risk
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of severe visual loss by 50% (1991). However the incidence of severe visual
loss was low in both groups (2.6% versus 3.7%).
Newer treatments for retinopathy
The recently licenced anti-VEGF therapies are a significant addition to our
armamentarium for management of diabetic macular oedema. The first anti-
VEGF drug, Bevacizumab was initially licenced as a drug to restrict vascular
growth in the management of colorectal cancer(Yilmaz, Cordero-Coma et al.
2011). This drug targets all isoforms of VEGF and is currently widely used as
an unlicensed treatment for diabetic macular oedema(Goyal, Lavalley et al.
2011). Ranibizumab is a fragment of the same parent molecule as
bevacizumab and is licenced for the management of macular degeneration
(Nguyen, Shah et al. 2009, Nguyen, Shah et al. 2010). There are no studies
directly comparing the efficacies of these two drugs in the management of
diabetic macular oedema. However, an indirect comparison by systematic
review of clinical trials concluded that there were no significant differences in
the efficacies of the two drugs (Ford, Elders et al. 2012).
Pathologic processes in retinopathy
Vascular endothelial growth factor (VEGF)
VEGF was first identified by Senger et al in 1983 and exists in several
isoforms termed as VEGF-A to D (Senger, Galli et al. 1983, Salcedo, Medina
et al. 2005). Of these VEGF-A is the most widely studied and implicated in a
number of disease processes (Silha, Krsek et al. 2005). VEGF belongs to the
family of platelet derived growth factors, the gene for which is located on the
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short arm of chromosome 6 (Takahashi and Shibuya 1997, Ferrara 2000).
VEGF is expressed in a number of tissues including lung, heart, kidney, liver,
brain, adrenals and gastric mucosa (Yamaguchi, Yano et al. 1998, Shi, Wang
et al. 2001). Its physiological actions include increased vascular permeability
and angiogenesis (Yamaguchi, Yano et al. 1998).
VEGF in diabetic retinopathy
A number of cell types in the retinal produce VEGF, out of which the Muller
cells and astrocytes generally produce the greatest amounts under hypoxic
conditions (Aiello, Avery et al. 1994, Hata, Nakagawa et al. 1995). Diabetic
retinopathy is characterised by an initial period of vascular injury and
increased vascular permeability, which is followed by neovascularisation
(Aiello, Gardner et al. 1998). All these changes in the retinal microvasculature
are associated with increased expression of VEGF (Duh and Aiello 1999).
High glucose levels are linked to oxidative stress leading to increased
production of VEGF (Kuroki, Voest et al. 1996, Ellis, Grant et al. 1998). There
is a strong correlation between ocular VEGF levels and development of
proliferative diabetic retinopathy (Duh and Aiello 1999). Furthermore, the
increased vascular permeability due to diabetes can be prevented or reversed
by blocking the VEGF pathway (Avery, Pearlman et al. 2006, Haritoglou,
Kook et al. 2006).
It is still unclear how the expression of VEGF gene is regulated in the setting
of diabetes. Mice studies have shown that hypoxia induces an up regulation of
the gene, but this effect is seen as early as a week after hypoxic insult (de
Gooyer, Stevenson et al. 2006). This is long before any microscopic changes
43
in the retina are evident. In addition to hypoxia, a number of inflammatory
mediators such as TNF-α, TGF-β and growth factors such as IGF-1 also 
induce up regulation of VEGF (Pertovaara, Kaipainen et al. 1994, Goad, Rubin
et al. 1996, Ryuto, Ono et al. 1996). This VEGF expression is mainly the result
of paracrine effects of the above mentioned factors.
Cardiovascular risk in type 2 diabetes
Markers of cardiovascular risk
It is well recognised that patients with diabetes are at high risk of adverse
cardiovascular events. Current management of patients with diabetes involves
managing the risk factors for cardiovascular disease in addition to glycaemic
control (2012). Hypertension, dyslipidaemia, smoking and obesity are well
validated markers of macrovascular disease (Cleary, Orchard et al. 2006). It
has been recognised recently that, body composition and insulin resistance are
sensitive markers of cardiovascular risk (Tai, Lau et al. 2000).
Body composition
Recently it has been recognised that adipose tissue is a complex endocrine
organ, possibly the largest in the human body, that releases a number of
adipokines that influence metabolic and cardiovascular risk factors (Kershaw
and Flier 2004). Total body fat mass, percentage of body fat and body fat
distribution, especially the degree of hepatic adiposity influence insulin
resistance and thereby modulate the risk of macrovascular complications in
subjects with diabetes (Kissebah, Vydelingum et al. 1982, Sato, Tamura et al.
2007, Vitola, Deivanayagam et al. 2009, Solomon, Haus et al. 2010). A
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number of techniques are available to estimate body composition such as bio-
electrical impedance, dual energy X-ray absorptiometry, quantitative computer
tomography, magnetic resonance spectroscopy and air displacement
plethysmography (Lee and Gallagher 2008). The choice of technique depends
on local availability and suitability to the experimental study.
Bio-electrical impedance analysis
Bio-electrical impedance analysis is a commonly used technique that measures
the resistance to a small electrical current as it travels through the total body’s
water pool (Lee and Gallagher 2008). An estimate of total body water is
acquired from which total body fat free mass is calculated. The most
commonly used technique is single frequency bio-impedance analysis that
provides limited data about body composition. Advances in technology had led
to multi-segmental bio-impedance spectroscopy that gives more sophisticated
data about fat distribution (Pateyjohns, Brinkworth et al. 2006). The
advantages of bio-impedance analysis include its ease of use, safety,
portability, relatively low cost and require minimal participant participation.
However this technique should not be used in subjects with a pacemaker in
situ.
Insulin sensitivity
Homeostatic model assessment (HOMA)
HOMA is a method for assessing β cell function and insulin sensitivity/insulin 
resistance from basal blood glucose and insulin concentrations. The HOMA
model is derived from a computer based mathematical assessment of the
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interaction between pancreatic islet function and insulin resistance. The output
is calibrated to normal β cell function of 100% and normal insulin resistance of 
1(Wallace, Levy et al. 2004). Experimental data from humans and animals
form the basis of predictions used in the model.
The uptake and output of glucose from the liver are modelled to depend on the
glucose and insulin levels. In HOMA insulin half-life is defined as 3.8 minutes
with an additional slower component(Bergman and Bucolo 1974). The glucose
uptake in fat and muscle is determined by the insulin concentration(Matthews,
Rudenski et al. 1985). In humans approximately half of the basal glucose
turnover is to the central nervous system, which is a glucose dependent process
(Rowe, Maxwell et al. 1959). Glucose uptake by the muscle and fat are
dependent on both glucose and insulin concentrations(Berger, Hagg et al.
1975).
HOMA2: the updated HOMA model
The currently used version HOMA2 has nonlinear solutions and accounts for
variations in hepatic and peripheral glucose resistance. In addition adjustments
are made to allow for an increase in insulin secretion if the plasma glucose is >
10 mmol/l. To further improve accuracy the effect of glycosuria due to
hyperglycaemia is also taken into account(Rudenski, Matthews et al. 1991).
The mean of 3 samples taken at 5 minute intervals is better than a single
sample, but this is often impractical. In larger datasets analysis of a single
sample give s comparable results to the mean of three samples(Wallace, Levy
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et al. 2004). As haemolysis degrades insulin, careful handling of the samples is
essential for accurate results.
Caveats for using HOMA
HOMA can be used to assess insulin sensitivity in subjects treated with
exogenous insulin, but it should be ensured that blood sampling is done when
glucose and insulin concentrations are in a steady state(Wallace, Levy et al.
2004). It is not appropriate to use HOMA to calculate β cell function in 
subjects treated with exogenous insulin. As HOMA is a measure of basal
insulin sensitivity and β cell function, it does not give information about the 
stimulated state (Wallace, Levy et al. 2004).
Incretins
Overview of incretins
It was noted that the insulin response following oral administration of glucose
was two to three times higher, when compared with the insulin response after
intravenous glucose (Holst and Orskov 2001). This phenomenon is due to the
‘incretin effect’ mediated by the gut derived hormones GLP-1 and GIP
(Nauck, Schmidt et al. 1989, Nauck, Bartels et al. 1993). The magnitude of
incretin effect depends on the glucose load ingested, thereby keeping blood
glucose levels stable (Nauck, Homberger et al. 1986). Both hormones have
short half-lives and are cleared from circulation by the enzyme DPP4(Meier,
Nauck et al. 2004).
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Figure 1.4: GRAPH DEPICTING THE INCRETIN EFFECT. The area under
the curve for insulin secretion is smaller in subjects with type 2 diabetes when
compared with controls.
Incretin based therapies
Experimental studies on humans have shown that the GLP-1 response to a
glucose load is reduced in patients with type 2 diabetes, whereas the GIP
response is relatively preserved (Vilsbøll, Krarup et al. 2001). This impaired
secretion of GLP-1 might contribute towards inappropriate insulin secretion in
type 2 diabetes. Treatments based on the incretin molecule GLP-1 are recent
additions to medical management of type 2 diabetes (Lovshin and Drucker
2009).
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The inhibitors of DPP4 enzyme (sitagliptin, vildagliptin, saxagliptin and
linagliptin) reduce the enzyme activity by up to 80% and prolong the action of
endogenous GLP-1. This generally produces a modest and transient rise in
post prandial blood concentrations of GLP-1 (Ahrén, Landin-Olsson et al.
2004, Herman, Stevens et al. 2005). The analogues of GLP-1 (exenatide,
liraglutide and lixisenatide) are resistant to enzymatic degradation by DPP4
enzyme. Following parenteral administration, these drugs achieve sustained
pharmacological blood concentrations, hence are more effective than DPP4
inhibitors in achieving glycaemic control (Drucker and Nauck 2006).
As GLP-1 and its analogues induce insulin secretion from the pancreatic β 
cells only when blood glucose levels are raised. Therefore, when used as
monotherapy or in combination with metformin, the chances of inducing
hypoglycaemia are minimal. The GLP-1 analogues and DPP4 inhibitors have
rapidly become an established component of the management of type 2
diabetes, due to their weight neutral/weight loss effects and due to their lower
propensity to cause hypoglycaemia (Lovshin and Drucker 2009).
Effects of GLP-1 beyond glycaemic control
Distribution of the GLP-1 receptor
The GLP-1 receptor has been found in a number of human tissues and organs,
such as brain, heart, breast, kidney, endothelium, lung and intestine (Körner,
Stöckli et al. 2007). The receptor is also expressed in certain tumours such as
pheochromocytomas. Although the principal action of GLP-1 is to regulate
insulin secretion, it also has a number of effects in various organ systems. By
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extension, the actions of long acting GLP-1 analogues are also manifested in
various tissues and organs.
Figure 1.5: CARTOON DEPICTING ACTION OF GLP-1 ON VARIOUS
ORGAN SYSTEMS. The chief actions of incretin hormones are to induce
insulin secretion, delay gastric emptying and induce satiety.
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GLP-1 effects on blood pressure
Liraglutide Effect and Action in Diabetes (LEAD) are a series of large
randomised controlled trials comparing the effect of the long acting GLP-1
analogue liraglutide, with various treatments for type 2 diabetes (Parks and
Rosebraugh 2010). In these trials a modest (2 to 6 mmHg) reduction in systolic
blood pressure was noted in patients treated with liraglutide (Garber, Henry et
al. 2009, Nauck, Frid et al. 2009). There was no significant change in diastolic
blood pressure. It is possible that some of the improvement in systolic blood
pressure was due to the significant weight loss seen in subjects on liraglutide.
However, in at least one of the studies, the change in blood pressure was seen
before any weight loss was noted, suggesting an independent effect of the drug
(Russell-Jones, Vaag et al. 2009). In a clinical trial setting, patients treated
with exenatide also showed a trend towards lower blood pressures (Gill,
Hoogwerf et al. 2010).
Evidence from animal models suggests that the blood pressure lowering effect
of the incretins is due to the action on central and peripheral neural pathways
(Barragán, Eng et al. 1999). Part of the blood pressure lowering effect of GLP-
1 might be due to its diuretic and natriuretic actions (Crajoinas, Oricchio et al.
2011). Experiments using mice hearts have demonstrated secretion of atrial
natriuretic peptide (ANP) following activation of the GLP-1 receptor in the
atrium (Kim, Platt et al. 2013). Hence a role for gut-heart axis in regulating
blood pressure cannot be ruled out.
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GLP-1 effects on endothelium
Following treatment with exenatide, monocytes of rats showed a lower
propensity to adhere to the endothelium of isolated aortae (Arakawa, Mita et
al. 2010). In vitro studies have demonstrated the expression of GLP-1 receptor
on the vascular smooth muscle cells of humans (Goto, Nomiyama et al. 2011).
Treatment with exenatide significantly reduced the proliferation of cultured
smooth muscle cells that was induced by platelet derived growth factor (Goto,
Nomiyama et al. 2011).
In vitro studies have demonstrated that liraglutide attenuated the induction of
plasminogen activator inhibitor type-1 and vascular adhesion molecules in
human vascular endothelial cells (Gaspari, Liu et al. 2011). In vivo studies on
mice showed a significant improvement in endothelial dysfunction following
treatment with liraglutide (Gaspari, Liu et al. 2011). Advanced glycation end
products play an important role in the development of microvascular
complications of diabetes. GLP-1 inhibits the expression of the receptor for
advanced glycation end products on isolated human umbilical vein endothelial
cells in a dose dependent manner (Ishibashi, Matsui et al. 2010). Further in
vitro studies have shown that liraglutide exerts anti-oxidant and anti-
inflammatory effects on endothelial cells and up regulates protective anti-
oxidative enzymes (Shiraki, Oyama et al. 2012).
The effect of exenatide on post-prandial endothelial dysfunction was explored
in a study, involving 28 subjects with impaired glucose tolerance or recent
onset type 2 diabetes (Koska, Schwartz et al. 2010). In a double-blinded,
randomised cross-over design the subjects were given a single injection of
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exenatide or placebo before a high fat meal. The post prandial endothelial
function was significantly higher after exenatide. A large proportion (64%) of
this effect was attributed to the reduction in post prandial triglyceride levels
following exenatide.
These studies suggest that GLP-1 might have a significant role in modulating
the course of vascular complications of diabetes. Large scale human studies
have not yet been conducted to conclusively answer this question.
GLP-1 effects on cardiovascular system
In a clinical study, 10 patients and 11 matched controls were treated with a 72
hour infusion of GLP-1 or placebo. All the subjects had an ejection fraction
<40% following acute myocardial infarction and were treated with
angioplasty. The GLP-1 treated patients had a significant improvement in the
mean ejection fraction from 29% to 39% (p<0.01). The improvements in the
ejection fractions of GLP-1 treated subjects were evident in patients with and
in subjects with normal glucose homeostasis (Nikolaidis, Mankad et al. 2004).
In another randomized controlled trial, 172 patients with acute myocardial
infarction were randomised to receive either exenatide or placebo. Even
though the mean infarct size was smaller in the exenatide treated group, there
was no difference in the ventricular function or 30 day event rate (Lønborg,
Vejlstrup et al. 2012). In patients with NYHA (New York Heart Association)
heart failure grades 3 or 4, infusion of GLP-1 significantly improved left
ventricular ejection fraction, VO2 max and six minute walk distance when
compared with placebo (Sokos, Nikolaidis et al. 2006). The exact mechanisms
mediating the effects of GLP-1 and its analogues on the heart are still unclear.
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GLP-1 and the nervous system
Part of the weight reducing effects of GLP-1 analogues is attributed to
induction of satiety by acting on the central nervous system. In an
experimental study on human volunteers, positron emission tomography was
employed to detect changes in blood flow to regions of brain. It was noted that
blood levels of GLP-1 were associated with increased blood flow to the left
dorsolateral prefrontal cortex and the hypothalamus, which are involved in
satiety and feeding responses (Pannacciulli, Le et al. 2007). There is ample
evidence that the increasing incidence of diabetes is due to the global rise in
the rates of obesity (Shaw, Sicree et al. 2010, Vinciguerra, Baratta et al. 2013).
The weight reducing effect of GLP-1 analogues makes them an attractive
option for the management of type 2 diabetes as most other anti-
hyperglycaemic drugs are either weight neutral or induce weight gain.
In vivo animal studies suggest that GLP-1 might have neuroprotective
properties. Administration of vildagliptin to rats slowed nerve fibre loss, when
compared with untreated rats. This suggests a possible beneficial effect of
incretin based therapies in diabetic neuropathy (Jin, Liu et al. 2009). In a
rodent model of Parkinson’s disease, exenatide promoted neurogenesis and
restored dopaminergic imbalance in the basal ganglia (Bertilsson, Patrone et
al. 2008).
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Renal effects of GLP-1
Experiments on obese humans have shown that short term infusion of GLP-1
enhances renal sodium loss and reduces hyperfiltration. This suggests a
possible action on the proximal tubule, which is the major site of sodium
reabsorption (Gutzwiller, Tschopp et al. 2004). There is evidence suggesting
that GLP-1 acts on the sodium/hydrogen exchanger on the proximal tubule
(Crajoinas, Oricchio et al. 2011). However, it is not known whether this effect
persists with continued administration of GLP-1 analogues. DPP4 inhibitors
have also been shown to have natriuretic properties and hence might be a
treatment option for salt-sensitive hypertension (Tanaka, Nangaku et al. 2011).
In vitro studies on mesangial cells indicate that GLP-1 might protect the renal
cells from inflammatory damage due to advanced glycation end products
(Ishibashi, Nishino et al. 2011). Administration of exenatide to rats for 8
weeks reduced albuminuria and glomerular hyperfiltration. In addition
structural changes such as amelioration of glomerular hypertrophy were also
noted. These effects were not linked to changes in glycaemia or blood pressure
and were possibly mediated by modulation of pro-inflammatory cytokines
(Kodera, Shikata et al. 2011).
These findings are very exciting in the context of management of diabetic
nephropathy. Current management of diabetic nephropathy is based on
optimizing glycaemic control and treatment of blood pressure.
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On-going research is focussed on discovering drugs acting on inflammatory
pathways involved in the pathogenesis of nephropathy, therefore, the GLP-1
based drugs might present an interesting option.
GLP-1 and gastro-intestinal tract
In a human study, the gastric volumes were evaluated by single photon
emission tomography following intravenous infusion of GLP-1. When
compared to controls the gastric volumes were higher in subjects who had
GLP-1 (Delgado-Aros, Kim et al. 2002). Slowing of gastric emptying is one of
the proposed mechanisms responsible for the glucose lowering effect
(Marathe, Rayner et al. 2011). However continuous activation of the GLP-1
receptor on the stomach might result in reduced responsiveness. Indeed, the
changes in gastric motility induced by long acting version of exenatide are
smaller than the reductions achieved by twice daily injections of exenatide
(Drucker, Buse et al. 2008).
In clinical practice, the most common adverse effects of GLP-1 analogues are
related to the upper gastrointestinal tract and are thought to be due to gastric
distension. Up to a quarter of patients started on liraglutide report nausea and
vomiting, however symptoms persist in only 5-10% of patients after 4 weeks
of continued therapy (Garber, Henry et al. 2009). In about 5% of patients,
these adverse effects might be severe, requiring discontinuation of the drug
(Garber, Henry et al. 2009, Marre, Shaw et al. 2009, Nauck, Frid et al. 2009).
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GLP-1 and the exocrine pancreas
Recent publications have initiated a debate about the effects of GLP-1 on the
exocrine pancreas, specifically about the risks of pancreatic cancer and
pancreatitis (Barnett and O'Hare 2013). Results of a large retrospective study
suggested that treatment with exenatide or sitagliptin might increase the risk of
pancreatitis (Elashoff, Matveyenko et al. 2011). However it should be noted
that the study did not control for confounding factors such as obesity, alcohol
consumption and smoking. Another population based case-control study which
was designed to control for the above mentioned factors indicated a twofold
increased risk of pancreatitis with these drugs (Singh, Chang et al. 2013).
Pooled analyses of multiple studies involving a number of GLP-1 analogues
and DPP4 inhibitors did not show any increased risk of pancreatitis with these
classes of drugs (Shyangdan, Royle et al. 2011, Alves, Batel-Marques et al.
2012, Engel, Round et al. 2013, Monami, Dicembrini et al. 2013).
In toxicology studies mice were treated with vildagliptin for two years with
doses up to 200 times the recommended equivalent doses in humans.
Dysplastic changes were seen in the pancreata of mice at such high doses
(Busch, Hoffmann et al. 2013). The relevance of this finding to clinical
management using DPP4 inhibitors is questionable.
It is unclear whether there is a link between the uses of GLP-1 based therapies
and diseases of the exocrine pancreas. However it seems prudent that these
classes of drugs should be used with caution in patients at risk of pancreatic
disease due to other factors.
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GLP-1 and pancreatic β cell function 
Administration of exenatide to rats was associated with an increased first
phase glucose-stimulated insulin secretion after a period of 8 weeks.
Interestingly an expansion of β cell mass was also noted, which was achieved 
by an increase in proliferation and a reduction in apoptosis (Tourrel, Bailbé et
al. 2001). Similarly rats treated with liraglutide also showed improvement in β 
cell number and function (Shimoda, Kanda et al. 2011). Studies on obese
humans with type 2 diabetes suggest an improvement in β cell function under 
conditions of glucose-insulin homeostasis (Preumont, Hermans et al. 2010).
There is no evidence of β cell regeneration in humans.  
GLP-1 effects on metabolic rate
Studies on animal models suggests that GLP-1 might be involved in the
control of adipokine secretion and energy expenditure (Hansotia, Maida et al.
2007). Blocking the GLP-1 receptors in the brains of mice induced
hyperinsulinemia, insulin resistance and decreased energy expenditure. This
suggests that GLP-1 might play an important role in energy homeostasis
(Knauf, Cani et al. 2008). It has been proposed that GLP-1 is involved in post-
prandial energy expenditure, mediated by the lower brain stem and
sympathoadrenal system of rats (Osaka, Endo et al. 2005).
However these results have not been replicated in human studies. One
experimental study on healthy human volunteers found a positive correlation
between resting energy expenditure and fasting GLP-1 levels (Pannacciulli,
Bunt et al. 2006). These results are difficult to interpret because GLP-1 is
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predominantly secreted in response to food and hyperglycaemia. Two human
studies involving obese and normal weight subjects did not show any change
in energy expenditure after treatment with liraglutide (Harder, Nielsen et al.
2004, Horowitz, Flint et al. 2012).
GLP-1 effects on body composition
In a study involving subjects with mild obesity, short term treatment with
liraglutide showed an improvement in visceral adiposity as measured by bio-
electrical impedance analysis (Inoue, Maeda et al. 2011). A post-hoc analysis
of LEAD-2 and LEAD-3 trials confirmed these results. Significant reductions
in total fat mass and percentage of body fat were noted. In the subgroup of
patients on liraglutide 1.8 mg/day, a significant change in liver-to-spleen
attenuation ratio was seen, indicating a reduction in hepatic steatosis (Jendle,
Nauck et al. 2009). Treatment with exenatide for 1 year significantly reduced
body weight by 6%. Interestingly the reductions in total body fat and trunkal
fat mass were 11% and 15% respectively. In addition, exenatide increased total
adiponectin by 12%, independent of changes in total body weight or body fat
mass (Bunck, Cornér et al. 2010). These results indicate that GLP-1 analogues
might preferentially reduce adiposity in obese subjects. All the above
mentioned studies were done on human subjects who were either overweight
or had a mild degree of obesity. Studies have not yet explored the effect of
these drugs on subjects with morbid obesity.
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Hypothesis
The microvascular complications of diabetes are responsible for much of the
morbidity due to the disease. There is good evidence that the risks of diabetic
nephropathy and retinopathy are mitigated by achieving tight glycaemic
control and appropriate management of blood pressure. Recent evidence
suggests that inflammation and endothelial dysfunction play a pivotal role in
the development and progression of these complications. In vitro studies
indicate that the recently licenced GLP-1 analogues have anti-inflammatory
properties and improve endothelial function. Indeed, work on animal models
suggests that GLP-1 analogues slow the onset and progression of diabetic
nephropathy and improve outcomes in diabetic retinopathy. Hence, I
hypothesised that the GLP-1 analogue, liraglutide might replicate this
beneficial effect in humans.
Previous human studies have shown an improvement in body composition and
in markers of cardiovascular risk following treatment with liraglutide. Almost
all studies have been performed on subjects who were classed as overweight or
had a mild degree of obesity. Clinical studies have not included patients with
morbid obesity who have the highest levels of cardiovascular risk. Hence, I
investigated whether liraglutide modulates the cardiovascular risk of patients
with type 2 diabetes and morbid obesity.
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Aims
To investigate whether treatment with liraglutide
1. slows the progression of microalbuminuria in subjects with established
abnormal urinary albumin excretion
2. influences the rate of progression of urinary albumin excretion in
normoalbuminuric subjects
3. changes the course of diabetic retinopathy in patients with type 2
diabetes
4. modulates cardiovascular risk and body composition in morbidly obese
patients
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CHAPTER 2
METHODS
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Ethical approval
This research project was undertaken as a sub-study of the ‘Investigation of
metabolism in human participants’ project that is on-going at University
hospital of Coventry and Warwickshire. Formal ethical approval has been
granted for this study by the - Birmingham, East, North and Solihull regional
ethics committee (REC reference number: 11/H1206/3).
Retrospective Study
Retrospective data collection
Retrospective data was collected from the clinical case records of patients with
type 2 diabetes treated at University hospital of Coventry and Warwickshire
NHS trust. Case notes of all the patients who treated with liraglutide for at
least 6 months were requested for data collection. We collected baseline
anthropometric measurements prior to starting treatment with Liraglutide and
follow up data at 6 and 12 months. The laboratory results of these subjects at
baseline, 6 and 12 months were collected from the online Clinical Results
Reporting System. Baseline laboratory tests were defined as tests performed
not more than 4 weeks before commencement of treatment. Follow up
laboratory results were included if they were performed within a 4 week
window period 6 months and 12 months after treatment was started . Patients
who were previously treated with any other GLP-1 analogue were excluded
from our study.
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Inclusion criteria
1. All patients with type 2 diabetes treated with liraglutide at University
hospital of Coventry and Warwickshire
Exclusion criteria
1. Age less than 18 years or more than 80 years.
2. Previous treatment with GLP-1 analogues.
3. No hospital record of baseline and 6 month post treatment
anthropometric and laboratory data.
A group of control subjects, who were not treated with liraglutide were
identified from the DIAMOND database system at the University hospital of
Coventry and Warwickshire NHS trust. The case records of these patients
were requested for data collection. Cases and controls were matched for
gender, age, duration of diabetes, baseline BMI, baseline HbA1c, baseline
systolic blood pressure, baseline diastolic blood pressure, baseline total
cholesterol and baseline urinary albumin/creatinine ratio. All cases and
controls were treated with an ACE-I/ARB for blood pressure and other anti-
hypertensive drugs if appropriate.
Inclusion criteria
1. All subjects with type 2 diabetes on DIAMOND database at University
hospital of Coventry and Warwickshire.
64
Exclusion criteria
1. Treatment with liraglutide or other GLP-1 analogues.
2. No 6 monthly record of anthropometric and laboratory data.
3. No record of annual retinal screening data.
Statistical analysis
Statistical analysis was done using SPSS version 21. Independent samples ‘t’
test was employed to detect any baseline differences in continuous variables
using ‘treatment with liraglutide’ as the grouping variable. Levene’s test was
employed to test for equality of variances in the two groups. Students’s or
Welch’s ‘t’ test was chosen based on the homogeneity of variance. Chi-square
test for independence was employed for baseline categorical variables.
I calculated the change in anthropometric measurements and laboratory data 6
months after treatment for the liraglutide treatment group. Similarly, changes
in the same parameters at 6 months were calculated for the controls. Change in
albumin/creatinine ration at 6 months was defined as the primary outcome
variable. Changes in BMI, HbA1c, total cholesterol, systolic and diastolic
blood pressures were defined as secondary outcome variables. Independent
samples ‘t’ test was employed to detect any significant change between groups
with ‘treatment with liraglutide’ as grouping variable. A ‘p’ value less than
0.05 was defined as indicating statistical significance.
12 month follow up data was available for a subgroup of patients who
continued treatment with liraglutide. This subgroup was again matched with an
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appropriate control group and statistical analysis was done as mentioned
previously.
Criteria for normal and abnormal urinary ACR
As suggested by the NICE guidelines, patients were classed as having
microalbuminuria if urinary Albumin/Creatinine ratio ≥ 2.5 mg/mmol for men 
and ≥ 3.5 mg/mmol for women. Data from cases and controls with established 
microalbuminuria were compared to detect the effect of liraglutide on
progression of nephropathy. Data from patients with albumin excretion in
urine but not diagnostic of microalbuminuria was analysed to detect the effect
of liraglutide on the onset of diabetic nephropathy.
Data collection for retinopathy study
For our retrospective retinopathy study, cases and controls were identified as
mentioned above. Patients with diabetes in the catchment area of University
hospital of Coventry and Warwickshire NHS trust are offered an annual retinal
photograph as part of a national screening program and the retinopathy grades
are recorded in the ‘OPTOMIZE’ database. The retinal photographs are graded
as per nationally agreed criteria for retinopathy (R0-no retinopathy, R1-
background retinopathy, R2-pre proliferative retinopathy, R3-proliferative
retinopathy), maculopathy (M0-no maculopathy, M1-presence of
maculopathy) and previous photocoagulation (P0-no photocoagulation, P1-
previous photocoagulation). From the database we recorded the grades for
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retinopathy, maculopathy and previous photocoagulation in addition to visual
acuity scores for all patients treated with liraglutide.
Subjects were included in the study if they had a retinal screening before
starting liraglutide and the interval between this initial retinal screening and
commencement of liraglutide was not more than 6 months. We recorded the R,
M and P grades of these subjects after 12 months if they continued treatment
with liraglutide. Subjects who had stopped taking liraglutide before the second
retinal photograph were excluded. For the control group we recorded two
consecutive retinal grades performed at least 12 months apart.
Prospective study
Patient recruitment for prospective study
Patients attending the WISDEM centre at University hospital of Coventry and
Warwickshire were invited to take part in the on-going human metabolism
research projects in the hospital. Patients who expressed interest were
contacted by me and my colleagues to discuss the study in more detail,
following which a copy of the information sheet was provided. The subjects
were asked to reflect for at least 24 hours before consenting to participate in
the study. All participants were requested to give a formal signed consent prior
to involvement in the research project.
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Inclusion criteria
1. All subjects with type 2 diabetes commencing treatment with
liraglutide form 01/11/2011 to 31/10/2012 at University hospital of
Coventry.
Exclusion criteria
1. Subjects less than 18 years or older than 80 years.
2. Previous treatment with GLP-1 analogues.
3. Unwilling to participate or unable to consent.
4. Unable to attend follow up visit after 3 months.
We prospectively studied a group of 20 subjects with type 2 diabetes treated
with liraglutide for at least 3 months at the discretion of their physician. All 20
of the subjects had hypertension and were treated with an ACE-1/ARB and
other anti-hypertensive medications if appropriate. In this group 11 (7 males
and 4 females) patients had established microalbuminuria at baseline and 9 (5
males and 4 females) patients had albumin excretion in urine, but not
diagnostic of microalbuminuria. Fasted blood and urine samples were
collected from all subjects before starting liraglutide and the same was
repeated after 3 months of treatment. In addition anthropometric data, clinical
biochemistry and body composition analysis were done on these patients
before starting treatment and 3 months after treatment. Assays for biomarkers
of diabetic nephropathy were performed on the plasma samples before and
after treatment.
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Body composition analysis using InBody 720 analyser
The body composition analyser, InBody 720 is accurate for all body types and
uses a diverse range of frequencies from 1 kHz to 1 mHz to estimate body
composition. The following precautions were taken in all our subjects before
body composition analysis was performed to standardize the results
1. No significant exercise or exertion prior to analysis
2. All subjects were analysed after an overnight fast
3. Measurements were done under normal room temperature (20-25 ◦C) 
4. Measurements were performed after urination and defecation
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Figure 2.1: CARTOON OF INBODY720 BODY COMPOSITION
ANALYSER
After recording the age and gender on the analyser, subjects were invited to
step on the foot electrode, with their heels on the circular foot electrode and
forefoot in contact with the fore foot electrode. Subjects were instructed to
hold the hand electrodes with their thumbs on the thumb electrode and stand
comfortably during the test forming a 15 degree angle between the arms and
the trunk. The results were stored on the computer connected to the analyser
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for future analysis. The InBody uses an 8-point tactile method, which separates
the current and voltage starting point. Thus measurement always begins at a
fixed point in the wrists and ankles, providing high reproducibility and correct
body impedance measurement because the contact resistance from the skin is
removed.
Figure 2.2: CARTOON DEPICTING ELECTRODE CONTACTS AND
MECHANISMS OF BIO-IMPEDANCE ANALYSIS. The 8 point analyser
involves 2 contacts in each of the four limbs facilitating accurate estimations
of body composition.
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Bio-Plex assay
Principle
I employed the luminex based Bio-Plex assays to measure the serum
concentrations of MCP-1, VEGF, sICAM-1 and sVCAM-1. The Bio-Plex
multiplex assays are immunoassays formatted on magnetic beads. The assay
principle is similar to a sandwich ELISA. Capture antibodies against the
molecule of interest are covalently coupled to the beads, which react with
human plasma samples. After multiple washes to remove unbound protein, a
biotinated detection antibody is added to create a sandwich complex.
Phycoerythrin bound to streptavidin is used as the fluorescent indicator in the
final detection complex.
Data from the reactions are acquired using the Luminex based Bio-Plex
system. When the assay suspension is drawn into the reader, a red (635 nm)
laser illuminates each bead to provide bead classification and assay
identification. Similarly a green (532 nm) laser induces the phycoerythrin to
generate a reporter signal which is detected by a photomultiplier tube. The
concentration of analyte bound to each bead is proportional to the median
fluorescence intensity of the reporter signal.
Multiple independent studies have noted a mean inter assay coefficient of
variability of 10-14% for multiplexed bead based assays for cytokine detection
(dupont, Wang et al. 2005, Dossus, Becker et al. 2009). Intra-assay precision
of duplicate wells for ICAM-1 and VCAM-1 is less than 10% (Stanford). The
Bio-Plex assay for MCP-1 was found to detect the molecule over a
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concentration range of 1.45-23735 pg/ml, therefore superior to ELISA which
had a detection range of 7.8-500 pg/ml. The mean coefficient of variability of
Bio-Plex MCP-1 assay was 7.02% in one study(Christianssona, Mustjokib et
al. 2014). The Bio-Plex VEGF assay has a detection range of 1.79-29354
pg/ml and mean coefficient of variability of 5.01% (Christianssona, Mustjokib
et al. 2014)
Preparation and assay technique
The Bio-Plex system was started up and calibrated as per the manufacturer’s
protocol. Lyophilized standard was reconstituted with 500 µl of standard
diluent, which was serially diluted to produce an eight-point standard curve
with a fourfold dilution between each point. For the human MCP-1 and human
VEGF assays, plasma samples were diluted fourfold with sample diluent. For
the human ICAM-1 and human VCAM-1 assays, the plasma samples were
diluted to 1:100 with sample diluent. Appropriate volumes of coupled beads
were calculated using the worksheet provided and diluted in assay buffer.
Using a multichannel pipette 50 µl of the diluted coupled beads was added to
each well of a 96 well plate. After adding 50 µl of the diluted standards, blanks
and plasma samples as appropriate to each well, the plate was incubated on a
shaker at room temperature for 30 minutes.
After washing three times with wash buffer, the prepared detection antibody
was added to each well and incubated on a shaker for 30 minutes. After
washing three times, the prepared streptavidin- phycoerythrin was added.
Following further 30 minute incubation and washing 125 µl of assay buffer
was added to each well.
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The plate was formatted in the Bio-plex software to identify the wells with
standards, blanks and plasma samples. Data acquisition was set to 100 beads
per region for MCP-1 and VEGF assays. For ICAM-1 and VCAM-1 assays,
the data acquisition was set to 50 beads per region. For all the assays sample
size was set to 50 µl and DD gates set to 5000 (low) and 25000 (high). Data
acquired from the plate reader was analysed as described in detail in results
section.
Assay for hsCRP
Principle
The Tina-quant immunoturbidimetric assay employed to measure hsCRP in
human plasma samples on Roche analysers. The assay is based on the
principle of particle enhanced immunological agglutination. Anti-CRP
antibodies coupled to latex microparticles react with antigen in the plasma
sample to form an antigen/antibody complex. Following agglutination, this is
measured turbidimetrically.
Independent verification by FDA noted that inter-assay coefficient of variation
ranged from 0.6% to 1.3%, whereas inter-assay coefficient of variability
ranged from 2.2% to 3.5 (FDA). The analytical sensitivity (lower detection
limit) of the assay was 0.1 mg/L and functional sensitivity (limit of
quantitation) was 0.3 mg/L (FDA). The assay was accurate even in the
presence of haemolysis, icterus, paraproteins or lipemia.
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Assay technique
Reagent 1 for the assay is Tris(hydroxymethyl)-aminomethane buffer 16
mmol/l, pH 7.4 to form reagent 1. Reagent 2 comprises of latex particles
coated with anti-CRP mouse monoclonal antibodies: 0.1%; glyceine buffer: 50
mmol/l, pH 8.0. Reagents 1 and 2 are added to human plasma to start the
reaction. The Roche/Hitachi 902 analyser is caliberated with Preciset serum
proteins, Cal 2. After appropriate incubation the assay is run on the analyser.
The measurement range of hsCRP on this assay is 0.1 to 20 mg/l.
Assay for insulin
Principle
Immunoassay for quantification of insulin in human plasma was done using
the Elecsys assay which employs two monoclonal antibodies that are specific
for human insulin. This is a sandwich ELISA assay.
The Diabetes Research Unit at Cardiff University conducted an independent
study on the various commercially available insulin assays in the UK. The
coefficient of variability of the above mentioned assay ranged from 1.1% to
1.7%. Sensitivity of the assay was 1.4 pmol/L and the upper limit was 6945
pmol/L (Manley, Stratton et al. 2007).
Insulin from a 20 µl plasma sample, a biotinated monoclonal insulin-specific
antibody, and a monoclonal insulin specific antibody labelled with a ruthenium
complex form a sandwich complex. After addition of streptavidin coated micro
particles, the complex becomes bound to the solid phase via interaction biotin
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and streptavidin. The reaction mixture is aspirated into the measuring cell
where the micro particles are magnetically captured onto the surface of the
electrode. Unbound substances are removed with ProCell. Application of
electric current then induces chemiluminescent emission. This is quantified
using a photo multiplier.
Calibration
The calibration is instrument specifically generated by a 2 point calibration
and a master curve provided via the reagent barcode. Samples and calibrators
were at ambient temperature of 20-25 centigrade before measurement. Due to
possible evaporation effects, samples and calibrators were analysed within 2
hours.
Reagents and technique
M- Streptavidin coated micro particles 0.72 mg/ml
R1- Biotinated anti-insulin monoclonal antibody 1 mg/l, MES buffer 50
mmol/l, pH 6.0.
R2- Monoclonal mouse anti-insulin antibody labelled with ruthenium complex
1.75 mg/l, MES buffer 50 mmol/l, pH6.0.
Human plasma is incubated with R1 and subsequently with R2 for appropriate
periods to form a sandwich complex. After a further incubation with
streptavidin, the assay is read on the modular analytics E170 analyser. The
measurement range for insulin on the assay is 1.39-6945 pmol/l.
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CHAPTER 3
EFFECT OF LIRAGLUTIDE ON PROGRESSION
OF URINARY ALBUMIN EXCRETION IN
PATIENTS WITH TYPE 2 DIABETES MELLITUS
AND ESTABLISHED MICROALBUMINURIA
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Introduction
Diabetes is currently the most common cause of end stage renal failure in the
western world due to the rapid increase in the prevalence of diabetes,
especially type 2 diabetes. In addition the life expectancy of patients with
diabetes is increasing, hence the propensity to develop chronic complications
such as diabetic nephropathy also increases (Molitch, DeFronzo et al. 2004).
The majority of expenditure attributable to diabetes is not related to direct
glycaemic control, but is mainly due to chronic complications and associated
medical conditions(1998). Hence it is important to prevent development of
chronic complications and to limit their progression if already present.
Microalbuminuria is the earliest clinical indicator and most reliable marker of
diabetic nephropathy. It is defined as a urinary albumin/creatinine ratio (ACR)
of >2.5 mg/mmol in men and >3.5 mg/mmol in women. Established
microalbuminuria is confirmed if an abnormal urinary ACR is detected on at
least two occasions within 3-4 months(National Collaborating Centre for
Chronic 2008). About 25% of patients develop microalbuminuria after 10
years of type 2 diabetes, and a smaller proportion have a progressive increase
in albuminuria(Adler, Stevens et al. 2003).
Good glycaemic control has been shown to slow the progression of
microalbuminuria(Reichard, Nilsson et al. 1993). Tight control of blood
pressure is another key element of management of patients with
microalbuminuria (1998). Anti-hypertensives that block the renin-angiotensin
system are thought to confer additional benefit over and above blood pressure
reduction in improving renal outcomes in subjects with established
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microalbuminuria (Brenner, Cooper et al. 2001, Casas, Chua et al. 2005,
Bilous, Chaturvedi et al. 2009). Other treatment options such as fenofibrate
and dietary protein restriction have been proposed, but their effectiveness is
questionable (Hansen, Tauber-Lassen et al. 2002, Ansquer, Foucher et al.
2005).
In animal models of diabetic nephropathy, GLP-1 based therapies have shown
promising results in mitigation of diabetes related renal damage (Ishibashi,
Nishino et al. 2011, Hendarto, Inoguchi et al. 2012). The effect is thought to be
due to modulation of low grade inflammation and endothelial dysfunction
which are associated with diabetic nephropathy.
Aim
In this study I explored the effect of the GLP-1 analogue liraglutide on
progression of urinary ACR in patients with established microalbuminuria.
Methods
In this single centre study, patients who were treated with liraglutide were
identified form patient database of University hospital of Coventry and
Warwickshire NHS trust. Clinical and anthropometric characteristics of these
patients were collected form their case records at baseline, at 6 months and at
12 months if the treatment was continued. In particular the urinary ACR of the
patients was recorded before treatment and 6 months after treatment.
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A group of controls were identified from the DIAMOND database system and
their characteristics were similarly recorded from the case records. Change in
urinary ACR over 6 months and over 12 months were compared between the
two groups using SPSS version 21 for statistical analysis.
402 patients treated with liraglutide at University hospital of
Coventry and Warwickshire NHS trust
179 patients had abnormal urinary ACR (>2.5
mg/mmol in men or >3.5 mg/mmol) in
women
91 patients were followed up for at least
6 months
43 patients had study outcome
dataset recorded at baseline, 6 and 12
months
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Primary outcome
1. Changes in urinary albumin creatinine ratios after 6 and 12 months.
Secondary outcome
1. Changes in BMI, HbA1c, total cholesterol, systolic and diastolic blood
pressures after 6 and 12 months
All patients attending the GLP-1 clinic to commence treatment with liraglutide
were invited to participate in the prospective study. Details of patient
recruitment are detailed in chapter 2-Methods. 24 patients had abnormal
urinary albumin creatinine ratios, out of which, 11 patients agreed to
participate in the study after. Fasted blood samples were collected from these
subjects before and 3 months after treatment with liraglutide. The plasma
901 patients had abnormal urinary ACR (>2.5
mg/mmol in men or >3.5 mg/mmol) in
women
2492 patients with type 2 diabetes at University hospital of
Coventry and Warwickshire NHS trust-DIAMOND database
491 patients were followed up for at least
12 months
41 patients were matched with
cases on baseline characteristics
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levels of ICAM-1, VCAM-1, MCP-1 and hsCRP were measured before and
after treatment. Each serum sample was assayed for the molecule of interest in
duplicate and the mean of the two values was used for statistical analysis. If
the duplicates varied by >10%, that particular sample was excluded from the
analysis. The details of these assays are discussed in chapter 2.
Primary outcomes
1. Changes in biomarkers of endothelial dysfunction (sICAM-1 an
sVCAM-1) after 3 months of treatment with liraglutide.
2. Changes in biomarkers of inflammation (hsCRP and MCP-1) after 3
months of treatment with liraglutide.
Secondary outcomes
1. Changes in urinary albumin creatinine ratios after 3 months of
treatment with liraglutide
2. Changes in BMI, HbA1c, total cholesterol, systolic and diastolic blood
pressures after 3 months of treatment with liraglutide.
Results
In a retrospective cohort study we compared the baseline albumin/creatinine
ratios of 43 patients (26 males, 17 females) with their albumin/creatinine ratios
after 6 months of treatment with liraglutide. A matched control group of 41
patients with type 2 diabetes who were not treated with liraglutide were used
as comparator. All cases and controls were treated with either an ACE-I or
ARB for hypertension. Baseline characteristics of the subjects are shown on
table 1.
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DOMAIN LIRAGLUTIDE
Mean
(Standard
Deviation)
CONTROL
Mean
(Standard
Deviation)
Significance
p=
Number 43 41
Males:Females
(number)
26:17 24:17 0.85 (NS)
Age
(years)
59.93 ± 7.98 64.17 ± 11.68 0.11 (NS)
Duration of Diabetes
(years)
14.24 ± 8.25 14.62 ± 10.18 0.85 (NS)
Weight
(kg)
110.79 ± 26.77 106.81 ± 20.30 0.44 (NS)
BMI
(kg/m2)
37.36 ± 7.67 37.42 ± 5.74 0.96 (NS)
HbA1c
(mmol/mol)
71.14 ± 15.81 64.68 ± 15.06 0.09 (NS)
Systolic Blood Pressure
(mm Hg)
148.77 ± 18.58 143.61 ±16.29 0.18 (NS)
Diastolic Blood Pressure
(mm Hg)
78.40 ± 12.88 76.61 ± 11.31 0.50 (NS)
Total Cholesterol
(mmol/L)
4.05 ± 0.85 4.37 ± 1.20 0.16 (NS)
Urinary
Albumin/Creatinine
(mg/mmol)
18.90 ± 23.33 14.62 ± 18.51 0.35 (NS)
Table 3.1: BASELINE CHARACTERISTICS OF CASES AND CONTROLS
WITH ABNORMAL ALBUMIN:CREATININE RATIO
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Normality of distribution of the baseline variables were assessed by
Kolmogorov-Smirov and Shapiro-Wilk tests using SPSS software (threshold
for significance was 0.05). If the ‘p’ values for both tests were non-significant,
these variables were considered normally distributed for the purpose of this
study.
After 6 months there was a statistically significant reduction the urinary
albumin excretion rates of subjects in both groups. The mean baseline ACR for
all participants (liraglutide treated group and control group) was 16.81
mg/mmol, whereas the mean ACR after 6 months was 11.18 mg/mmol. The
mean change in ACR was 5.63 mg/mmol (95% CI: 3.12 to 8.13, p<0.01).
Patients treated with liraglutide had greater reductions in their urinary
albumin/creatinine ratios, but the results were not statistically significant.
There was a significant reduction in HbA1c of 5.11 mmol/mol in the
liraglutide group, but an increase of 3.75 mmol/mol in the control group. In
addition there was a significant reduction in BMI of 1.02 kg/m2 in the
liraglutide group and in increase in BMI of 0.27 kg/m2 in the control group.
There was a trend towards statistically significant improvement in total
cholesterol levels post treatment in the liraglutide group. Results are shown on
table 2, figures 1 and 2.
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DOMAIN LIRAGLUTIDE
Mean difference
(Standard error)
CONTROL
Mean difference
(Standard error)
Significance
p=
Urinary
Albumin/Creatinine
(mg/mmol)
-6.90 ± 1.57 -4.29 ± 1.98 0.30 (NS)
BMI
(kg/m2)
-1.02 ± 0.27 +0.27 ± 0.14 0.001
HbA1c
(mmol/mol)
-5.11 ± 2.21 +3.75 ± 2.03 0.004
Systolic Blood Pressure
(mm Hg)
-4.92 ± 2.23 -3.90 ± 2.86 0.77 (NS)
Diastolic Blood
Pressure
(mm Hg)
-0.19 ± 1.72 -0.68 ± 1.90 0.84 (NS)
Total Cholesterol
(mmol/L)
-0.20 ± 0.08 +0.06 ± 0.11 0.06 (NS)
Table 3.2: CHANGES IN PRIMARY AND SECONDARY ENDPOINTS
FROM BASELINE TO 6 MONTH FOLLOW UP
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Figure 3.1: CHANGES IN ACR, HBA1C AND SYSTOLIC BP AFTER 6
MONTHS. Statistically significant improvements in HbA1c levels were noted
in the liraglutide treated group, when compared with controls. However the
differences in systolic blood pressures and urinary albumin/creatinine ratios
were not significant.
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Figure 3.2: CHANGES IN DIASTOLIC BP, BMI AND TOTAL
CHOLESTEROL AFTER 6 MONTHS. No statistically significant changes in
diastolic blood pressures, BMI or total cholesterol levels were noted in the
liraglutide treated group, when compared with controls.
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Hierarchical linear regression was performed to identify the predictors of a
change in urinary albumin excretion. Change in urinary albumin/creatinine
ratio was the specified dependent variable. Age, duration of diabetes, baseline
HbA1c, baseline urinary albumin/creatinine ratio, baseline systolic and
diastolic blood pressures were entered as independent variables at step1. After
controlling for these variables, change in HbA1c, changes in systolic and
diastolic blood pressures were entered as independent variables in step 2. After
step 2 the total variance explained by the model as a whole was 70%, F (9, 69)
=18.10, p<0.001. After controlling for all the above mentioned variables,
treatment with liraglutide was entered as the independent variable at step 3.
This did not explain any additional variance in urinary albumin/creatinine
ratio. In the final model baseline urinary albumin/creatinine ratio and change
in diastolic blood pressure were highly statistically significant. Baseline
urinary albumin/creatinine ratio had a higher predictive value (β=-0.84, 
p<0.001) than change in diastolic blood pressure (β=-0.19, p=0.018). In 
addition baseline HbA1c (β=-0.178, p=0.023) and baseline systolic blood 
pressure (β=-0.184, p=0.029) also influenced improvement in urinary 
albumin/creatinine ratio.
From the cohort of 43 patients who were treated with liraglutide for 6 months,
35 patients continued treatment for at least 12 months. This group of 35
patients were matched with suitable controls at baseline and the above
mentioned parameters were analysed at 12 month follow up.
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After 12 months the changes in urinary albumin/creatinine ratios did not differ
between the liraglutide treated group and the control group. After 12 months
the liraglutide treatment group showed a significant reduction in HbA1c of
4.44 mmol/mol, but in the control group an increase in HbA1c of 4.00
mmol/mol was noted. The reduction in BMI noted at 6 months in the
liraglutide group was maintained- the reduction in BMI at 12 months was 1.04
kg/m2. There were no statistically significant changes in total cholesterol,
systolic blood pressure and diastolic blood pressure between the two groups.
The results are displayed on table 3, figures 3 and 4.
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DOMAIN LIRAGLUTIDE
Mean difference
(Standard error)
CONTROL
Mean difference
(Standard error)
Significance
p=
Urinary
Albumin/Creatinine
(mg/mmol)
-5.04 (1.88) -7.17 (2.73) 0.52 (NS)
BMI
(kg/m2)
-1.04 ± 0.36 +0.08 ± 0.27 0.01
HbA1c
(mmol/mol)
-4.44 ± 2.68 +4.00 ± 2.59 0.02
Systolic Blood Pressure
(mm Hg)
-5.14 ± 2.23 -1.20 ± 2.80 0.20 (NS)
Diastolic Blood Pressure
(mm Hg)
-2.00 ± 1.91 +0.52 ± 2.39 0.41 (NS)
Total Cholesterol
(mmol/L)
-0.09 ± 0.11 -0.09 ± 0.15 0.99 (NS)
Table 3.3: CHANGES IN PRIMARY AND SECONDARY ENDPOINTS
FROM BASELINE TO 12 MONTH FOLLOW UP. Statistically significant
improvements in HbA1c and BMI were noted in the liraglutide treated patients
at 12 months, when compared with controls.
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Figure 3.3: CHANGES IN ACR, HBA1C AND SYSTOLIC BP AFTER 12
MONTHS. The primary endpoint-urinary albumin/creatinine ratio was
reduced in both liraglutide group and control group, however there was no
difference between groups. No significant differences in systolic blood
pressures were noted.
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Figure 3.4: CHANGES IN DIASTOLIC BP, BMI AND TOTAL
CHOLESTEROL AFTER 12 MONTHS. The significant improvement noted
at 6 months was maintained at 12 months. However no changes in diastolic
blood pressures and cholesterol levels were noted between groups.
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I prospectively investigated whether treatment with liraglutide modulates the
markers of endothelial dysfunction and inflammation, thereby influencing the
progression of nephropathy over the next few years. The above mentioned
biomarkers in serum were measured in 11 subjects (6 males and 5 females)
with established microalbuminuria at baseline and 3 months after treatment
with liraglutide. The results are shown on table 4 and figure 5.
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DOMAIN
n=11
BASELINE
Mean
(Standard
Deviation)
3 MONTHS
AFTER
LIRAGLUTIDE
Mean
(Standard
Deviation)
CHANGE AFTER 3
MONTHS Mean
(95% Confidence
intervals)
Significance.
p=
BMI
(kg/m2)
48.78 ± 17.55 46.86 ± 15.67 -1.91 (-3.56 to -0.27) 0.02
HbA1c
mmol/mol
74.18 ± 24.22 58.09 ± 12.66 -16.09 (-28.18 to -3.99) 0.01
Systolic Blood
Pressure
(mmHg)
153.60 ± 17.98 141.20 ± 16.00 -12.40 (-26.20 to +1.40) 0.07 (NS)
Diastolic Blood
Pressure
(mmHg)
79.00 ± 10.57 71.40 ± 11.98 -7.60 (-16.20 to +1.00) 0.08 (NS)
Total Cholesterol
(mmol/l)
4.00 ± 0.76 3.60 ± 0.84 -0.40 (-0.83 to +0.03) 0.07 (NS)
LDL Cholesterol
(mmol/l)
1.97 ± 0.50 1.73 ± 0.62 -0.23 (-0.58 to +0.11) 0.16 (NS)
Urinary
Albumin/Creatini
ne (mg/mmol)
6.15 ± 4.31 3.40 ± 4.03 -2.74 (-5.62 to +0.12) 0.06 (NS)
sICAM-1
(ng/ml)
949.25 ±
366.86
1018.34 ±
281.06
+69.09 (-125.24 to
+263.43)
0.44 (NS)
sVCAM-1
(ng/ml)
832.79 ±
304.48
950.61 ±
309.25
+117.81 (-17.82 to
+253.45)
0.08 (NS)
MCP-1
(pg/ml)
90.05 ± 30.42 104.02 ± 41.43 +13.97 (-4.58 to +32.53) 0.12 (NS)
hsCRP
(mg/l)
5.50 ± 4.27 5.12 ± 5.07 -0.37 (-4.36 to +5.11) 0.85 (NS)
Table 3.4: CLINICAL PARAMETERS AND SERUM BIOMARKERS IN
SUBJECTS WITH ABNORMAL URINARY ALBUMIN/CREATININE AT
BASELINE AND 3 MONTHS AFTER TREATMENT. There were
improvements in BMI and HbA1c level of liraglutide treated subjects.
However other clinical parameters were unchanged.
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Figure 3.5: BASELINE AND POST TREATMENT LEVELS OF
BIOMARKERS OF ENDOTHELIAL DYSFUNCTION. No significant
differences were noted in circulating levels of sICAM-1 and sVCAM-1 3
months post-treatment with liraglutide.
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Figure 3.6: BASELINE AND POST TREATMENT LEVELS OF
BIOMARKERS OF INFLAMMATION. No significant changes in circulating
levels of hsCRP or MCP-1 were noted 3 months post-treatment with
liraglutide.
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When compared with baseline values, there was no significant change in
plasma levels of sICAM-1, sVCAM-1, MCP-1 or hsCRP after treatment
(results shown on figures 5 and 6). There was a statistically significant
reduction in BMI and improvement in HbA1c at 3 months (results shown on
table 4). There was a trend towards improvement in systolic and diastolic
blood pressures after treatment (results shown on table 4).
Discussion
This is the first human study to investigate the effect of GLP-1 agonists on the
progression of urinary ACR. Although previous animal studies suggested a
possible protective effect of GLP-1 based treatments on progression of
nephropathy, our retrospective cohort study did not show any benefit.
Predictors of improvement in urinary ACR
Regression analysis of the data indicated that the total model was robust
explaining 70% of the primary outcome variable which was change in urinary
albumin/creatinine ratio. After controlling for the effects of age, duration of
diabetes, baseline blood pressures and baseline HbA1c, the most reliable
predictor of change in albumin excretion in our cohort was the baseline urinary
ACR. This is in keeping with a Japanese retrospective cohort study that
identified baseline urinary albumin/creatinine ratio as the most significant
predictor of progression of diabetic nephropathy (Forsblom, Groop et al. 1998,
Yamada, Komatsu et al. 2005). This indicates that patients with persistent
microalbuminuria were identified by the clinician and given targeted treatment
in an effort to improve the renal outcome.
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A Japanese study also identified baseline HbA1c and average systolic blood
pressure over 8 years as important predictors of regression in urinary albumin
excretion (Yamada, Komatsu et al. 2005). In our cohort we have confirmed
that baseline HbA1c is a key parameter in altering the course of diabetic
nephropathy. In addition we identified that, change in diastolic blood pressure
is an independent predictor of change in urinary albumin excretion. It is well
known that tight blood pressure control in patients with hypertension and type
2 diabetes achieves a clinically important reduction in the progression of
microalbuminuria(1998, Cooper 1998, Gray, Raikou et al. 2000). Drugs acting
on the renin-angiotensin axis are currently the first line treatment for patients
with diabetes and microalbuminuria and might possible confer benefits over
and above simple blood pressure reduction (Brenner, Cooper et al. 2001, Chan,
Wat et al. 2004, Jerums, Allen et al. 2004, Casas, Chua et al. 2005). In our
study population all patients were treated with either an angiotensin convertase
inhibitor or angiotensin receptor blocking drug as per guidelines.
Diabetic nephropathy is a chronic complication that gradually progress over
years or decades. It is estimated that about 80% of patients with established
microalbuminuria have an increase in their urinary albumin excretion by 10-
20% every year. This happens over a period of 10-15 years culminating in
clinical albuminuria and is associated with a gradual rise in blood pressure
(Molitch, DeFronzo et al. 2004). Urinary albumin is the most widely used
marker of diabetic nephropathy in clinical practice and correlates well with
progression of diabetes related renal injury (Bakker 1999). In our cohort of
patients with established microalbuminuria, treatment with liraglutide for up to
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12 months did not make any significant change in urinary albumin/creatinine
ratio. In view of the long natural history of the disease it is possible that one
year is too short a period to detect a significant change. A longitudinal study
lasting several years is required to conclusively demonstrate whether
liraglutide has an effect on urinary albumin excretion rate. However a trend
towards the rate of progression of nephropathy might be indicated by certain
biomarkers.
In this study a significant improvement in the mean HbA1c was noted in the
liraglutide treatment group when compared with the control group. This is
possibly due to the increased frequency of healthcare contacts in the liraglutide
treatment group. Several previous studies have noted improvements in
diabetes control that were directly attributed to greater input from healthcare
professionals (Kaufman, Halvorson et al. 1999, Wagner, Grothaus et al. 2001).
Markers of inflammation and endothelial dysfunction
It has been shown that endothelial dysfunction and inflammation predate the
onset and progression of diabetic nephropathy. A rise in serum levels of
sICAM-1 and sVCAM-1 which are bio-markers of endothelial dysfunction has
been noted several years before an increase urinary albumin excretion was
detected (Astrup, Tarnow et al. 2008, Persson, Rossing et al. 2008).
Conversely, lower levels of these markers are associated with slower
progression of nephropathy (Chow, Nikolic-Paterson et al. 2005). Several
cross-sectional studies in humans have shown a significant correlation between
biomarkers of inflammation such as hsCRP and MCP-1 and severity of urinary
albumin excretion (Chiarelli, Cipollone et al. 2002, Kiyici, Erturk et al. 2006,
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Goldberg 2009, Kajitani, Shikata et al. 2010). Blood level of hsCRP is a well-
known marker of micro inflammation and is closely related to severity of
diabetic nephropathy (Kajitani, Shikata et al. 2010). The irbesartan in patients
with type 2 diabetes and microalbuminuria study was a 2 year prospective,
randomized controlled trial that compared irbesartan with placebo. The
primary end point was time to onset of diabetic nephropathy. A post-hoc,
analysis of data from the study suggested that hsCRP might predict
progression of microalbuminuria (Persson, Rossing et al. 2008). Some of these
biomarkers have been studied in animal models.
Diabetic rats treated with exendin-4 for 8 weeks showed a significant
improvement in the urinary albumin excretion rate when compared with
controls. This improvement was noted even though there was no significant
change in fasting glucose or glycated haemoglobin. Renal histology
demonstrated that glomerular hypertrophy, mesangial matrix expansion and
inflammatory cell infiltration in the kidney were lower in the exendin-4 treated
rats (Park, Kim et al. 2007). In a rat model of diabetic nephropathy, the
injection of GLP-1 agonist exendin-4 exerted renoprotective effects through an
anti-inflammatory action. Exendin-4 acted directly on the GLP-1 receptor in
the rat kidney and attenuated the production of pro inflammatory cytokines
and ICAM-1(Kodera, Shikata et al. 2011). Rats with diabetes treated with
subcutaneous injections of liraglutide for 4 weeks showed a reduction in
oxidative stress markers, transforming growth factor-β and urinary albumin 
excretion (Hendarto, Inoguchi et al. 2012).
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Sitagliptin is a selective inhibitor of the enzyme dipietidyl pepdidase-4 which
inactivates GLP-1. Spontaneously hypertensive rats treated with sitagliptin
showed an improvement in endothelium dependent relaxation of renal arteries
and restored renal blood flow. Ex vivo exendin-4 treatment also improved
endothelial function of renal arteries from human subjects with hypertension
(Liu, Liu et al. 2012).
Thus there is a significant body of evidence from animal models and ex vivo
studies suggesting that GLP-1 might modulate the course of diabetic
nephropathy. We hypothesised that liraglutide treatment in human subjects
with type 2 diabetes might have an impact on the biomarkers of endothelial
dysfunction (ICAM-1 and VCAM-1) and inflammation (MCP-1 and hsCRP),
thereby altering the progression of microalbuminuria. But in our prospective
study involving 11 human subjects with type 2 diabetes and established
microalbuminuria, there was no change in the serum levels of the above
mentioned biomarkers before and 3 months after treatment with liraglutide.
Conclusion
In patients with type 2 diabetes and established microalbuminuria, treatment
with liraglutide does not influence the progression of urinary albumin
excretion. It is known that glomerular hyperfiltration and hyperperfusion
associated with subtle morphological changes in the glomerular basement
membrane and mesangium occurs many years prior to appearance of abnormal
urinary albumin excretion(Cooper 1998). It is estimated that subjects who are
normoalbuminuric at the time of diagnosis of diabetes remain free of overt
nephropathy for about 19 years(Adler, Stevens et al. 2003). To further evaluate
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the influence of liraglutide in diabetic nephropathy we studied its effect in a
group of subjects with normal urinary albumin excretion. This is discussed in
the next chapter.
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CHAPTER 4
EFFECT OF LIRAGLUTIDE ON DEVELOPMENT
OF MICROALBUMINURIA IN PATIENTS WITH
TYPE 2 DIABETES AND NORMAL URINARY
ALBUMIN EXCRETION RATES
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Introduction
Diabetes related renal injury goes through several distinct phases of
development. Functional changes in the nephron in the form of hyperperfusion
and glomerular hyperfiltration occur before there are any detectable structural
or clinical changes (Mauer, Steffes et al. 1984). Hyperfiltration is due to a
decrease in resistance offered by the afferent and the efferent arterioles, the
reduction being greater in the efferent arteriole (Ziyadeh and Wolf 2008).
Many factors are involved in this defective auto regulation including
angiotensin 2, cytokines and pro inflammatory molecules (Wolf, Kalluri et al.
1999, Wolf and Ziyadeh 1999, Ziyadeh and Wolf 2008). Hyperfiltration leads
to appearance of albumin in the urine, which over a period of time gradually
increases to become pathological.
Work on animal models suggests that GLP-1 analogues may prevent disease
progression in the early stages of albuminuria (Kodera, Shikata et al. 2011).
This is thought to be due to modulation of inflammation and endothelial
dysfunction. In this study I explored the effect of liraglutide on early diabetes
related renal injury in subjects with type 2 diabetes.
Aim
In this study I explored the effect of the GLP-1 analogue liraglutide on
progression of urinary ACR in patients with detectable urinary albumin
excretion, but not diagnostic of pathological microalbuminuria.
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Methods
This study was similar to the study on the effect of liraglutide on progression
of microalbuminuria in patients with type 2 diabetes. I included patients with
type 2 diabetes and normoalbuminuria who were treated with liraglutide for at
least 6 months. Cases selection for the retrospective study is shown in the
flowchart below.
233 patients had normal urinary ACR (<2.5
mg/mmol in men or <3.5 mg/mmol) in
women
131 patients were followed up for at least
6 months
63 patients had study outcome
dataset recorded at baseline, 6 and 12
months
402 patients treated with liraglutide at University hospital of
Coventry and Warwickshire NHS trust
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They were compared with a matched group of subjects who were not treated
with liraglutide. Controls were selected from the database of patients with type
2 diabetes on the DIAMOND database at University hospital of Coventry and
Warwickshire. Selection of controls is shown in the flowchart below.
Primary outcome
2. Changes in urinary albumin creatinine ratios after 6 and 12 months.
Secondary outcome
2. Changes in BMI, HbA1c, total cholesterol, systolic and diastolic blood
pressures after 6 and 12 months
1591patients had abnormal urinary ACR
(>2.5 mg/mmol in men or >3.5 mg/mmol) in
women
702 patients were followed up for at least
12 months
56 patients were matched with
cases on baseline characteristics
2492 patients with type 2 diabetes at University hospital of
Coventry and Warwickshire NHS trust-DIAMOND database
106
All patients attending the GLP-1 clinic to commence treatment with liraglutide
were invited to participate in the prospective study. Details of patient
recruitment are detailed in chapter 2-Methods. 25 patients had
normoalbuminuria, out of which, 9 patients agreed to participate after
informed consent. The biomarkers of diabetes related kidney injury were
measured before and 3 months after treatment with liraglutide.
Each serum sample was assayed for the molecule of interest in duplicate and
the mean of the two values was used for statistical analysis. If the duplicates
varied by >10%, that particular sample was excluded from the analysis.
Primary outcomes
3. Changes in biomarkers of endothelial dysfunction (sICAM-1 an
sVCAM-1) after 3 months of treatment with liraglutide.
4. Changes in biomarkers of inflammation (hsCRP and MCP-1) after 3
months of treatment with liraglutide.
Secondary outcomes
3. Changes in urinary albumin creatinine ratios after 3 months of
treatment with liraglutide
4. Changes in BMI, HbA1c, total cholesterol, systolic and diastolic blood
pressures after 3 months of treatment with liraglutide.
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Results
In a retrospective cohort study, baseline and 6 month follow up data was
collected for a group of 63 patients (30 males, 33 females) with
normoalbuminuria, who were treated with liraglutide. They were matched with
56 patients (29 males, 27 females) with type 2 diabetes who were not treated
with liraglutide. All cases and controls were treated with either an ACE-I or
ARB for hypertension. Baseline characteristics of the study groups are shown
on table 1.
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DOMAIN LIRAGLUTIDE
Mean (Standard
Deviation)
CONTROL
Mean (Standard
Deviation)
Number 63 56
Males:Females
(number)
30:33 29:27
Age
(years)
58.92 ± 8.55 61.96 ± 9.23
Duration of Diabetes
(years)
12.43 ± 8.29 12.13 ± 8.02
Weight
(kg)
107.73 ± 21.33 101.49 ± 17.60
BMI
(kg/m2)
38.54 ± 5.96 36.61 ± 4.60
HbA1c
(mmol/mol)
70.43 ± 17.49 64.66 ± 14.28
Systolic Blood Pressure
(mm Hg)
144.03 ± 18.81 137.98 ± 15.02
Diastolic Blood Pressure
(mm Hg)
76.68 ± 10.56 77.07 ± 12.26
Total Cholesterol
(mmol/L)
4.26 ± 0.99 4.19 ± 0.97
Urinary
Albumin/Creatinine
(mg/mmol)
0.81 ± 0.49 0.97 ± 0.57
Table 4.1: BASELINE CHARACTERISTICS OF CASES AND CONTROLS
WITH NORMAL ALBUMIN:CREATININE RATIO
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Normality of distribution of the baseline variables were assessed by
Kolmogorov-Smirov and Shapiro-Wilk tests using SPSS software (threshold
for significance was 0.05). If the ‘p’ values for both tests were non-significant,
these variables were considered normally distributed for the purpose of this
study.
After 6 months there was a statistically significant reduction the urinary
albumin excretion rates of subjects in both groups. The mean baseline ACR for
all participants (liraglutide treated group and control group) was 0.88
mg/mmol, whereas the mean ACR after 6 months was 1.02 mg/mmol. The
mean change in ACR was 0.138 mg/mmol (95% CI: -0.21 to -0.01, p=0.048).
At 6 months, the mean albumin/creatinine ratio in the liraglutide group was
reduced by 0.03 mg/mmol, whereas it increased by 0.29 mg/mmol in the
control group. This showed a trend towards statistical significance with a p
value of 0.06. Change in BMI was significantly different with a decrease in
BMI of 1.28 kg/m2 in the liraglutide group and an increase in BMI of 0.15
kg/m2 in the control group. The patients in liraglutide group had a reduction in
mean HbA1c of 7.53 mmol/mol, whereas in the control group mean HbA1c
increased by 3.00 mmol/mol. No statistically significant changes in systolic
blood pressure, diastolic blood pressure or change in total cholesterol were
noted between the two groups. The results are shown on table 2, figures 1 and
2.
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DOMAIN LIRAGLUTIDE
Mean difference
(Standard error)
CONTROL
Mean difference
(Standard error)
Significance
p=
Urinary
Albumin/Creatinine
(mg/mmol)
-0.03 ± 0.06 +0.29 ± 0.15 0.072
BMI
(kg/m2)
-1.28 ± 0.24 +0.15 ± 0.13 0.00
HbA1c
(mmol/mol)
-7.53 ± 1.44 +3.00 ± 1.49 0.00
Systolic Blood Pressure
(mm Hg)
-3.57 ± 1.98 -0.07 ± 1.52 0.17
Diastolic Blood Pressure
(mm Hg)
-1.17 ± 1.28 +0.57 ± 1.15 0.31
Total Cholesterol
(mmol/L)
-0.31 ± 0.11 -0.18 ± 0.08 0.36
Table 4.2: CHANGES IN PRIMARY AND SECONDARY ENDPOINTS
FROM BASELINE TO 6 MONTH FOLLOW UP. There were significant
improvements in the primary endpoint-change in urinary albumin/creatinine
ratios in both the liraglutide group and control group. However no significant
chnages were noted between the two groups.
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Figure 4.1: CHANGES IN ACR, BMI AND TOTAL CHOLESTEROL
AFTER 6 MONTHS. After 6 months, significant improvements in BMI were
noted in the liraglutide treatment group, however no changes were evident in
total cholesterol or urinary albumin/creatinine ratios.
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Figure 4.2: CHANGES IN HBA1C, SYATOLIC AND DIASTOLIC BLOOD
PRESSURES AFTER 6 MONTHS. There was a significant improvement in
HbA1c in the liraglutide treated group when compared with controls. However
no changes in systolic or diastolic blood pressures were evident.
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Out of the 63 patients treated with liraglutide for 6 months, 57 continued
treatment for at least 12 months. Baseline characteristics of this group of 57
patients were matched with a group of 57 controls and the above noted
parameters were analysed at 12 months. After 12 months the changes in
albumin/creatinine ratios was not statistically different between the liraglutide
treatment group and the control group. The liraglutide treated patients
maintained the statistically significant reductions in BMI and HbA1c that were
noted at 6 months. No statistically significant changes in systolic blood
pressure, diastolic blood pressure or total cholesterol were evident between the
two groups. The results are shown on table 3, figures 3 and 4.
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DOMAIN LIRAGLUTIDE
Mean difference
(Standard error)
CONTROL
Mean difference
(Standard error)
Significance
p=
Urinary
Albumin/Creatinine
(mg/mmol)
-0.07 ± 0.10 -0.35 ± 0.13 0.11
BMI
(kg/m2)
-1.26 ± 0.26 +0.27 ± 0.17 0.00
HbA1c
(mmol/mol)
-5.09 ± 1.56 +3.28 ± 1.51 0.00
Systolic Blood Pressure
(mm Hg)
-2.80 ± 1.65 -1.54 ± 1.93 0.62
Diastolic Blood Pressure
(mm Hg)
-1.75 ± 1.37 -2.80 ± 1.44 0.59
Total Cholesterol
(mmol/L)
-0.04 ± 0.12 -0.12 ± 0.07 0.60
Table 4.3: CHANGES IN PRIMARY AND SECONDARY ENDPOINTS
FROM BASELINE TO 12 MONTH FOLLOW UP. Statistically significant
reductions in urinary albumin/creatinine ratios were evident in both groups,
but no differences were noted between groups.
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Figure 4.3: CHANGES IN ACR, DIASTOLIC BLOOD PRESSURE AND TOTAL
CHOLESTEROL AFTER 12 MONTHS. Changes in total cholesterol and diastolic
blood pressures were not different between groups.
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Figure 4.4: CHANGES IN BMI, SYSTOLIC BLOOD PRESSURE AND
HBA1C AFTER 12 MONTHS. Significant improvements in mean BMI and
HbA1c were noted in the liraglutide treated patients when compared with
controls. No differences in systolic blood pressures were evident between
groups.
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Hierarchical logistic regression was performed to assess whether liraglutide
treated subjects had a significant change in urinary albumin excretion. The
specified dependent variable was improvement or worsening of urinary ACR
after 12 months. Age, duration of diabetes, baseline HbA1c, baseline urinary
albumin/creatinine ratio, baseline systolic and diastolic blood pressures were
entered as independent variables at step1. After controlling for these variables,
change in HbA1c, changes in systolic and diastolic blood pressures were
entered as independent variables in step 2. After step 2 the total variance
explained by the model as a whole was 17%, F (9, 96) =2.10, p=0.036. After
controlling for all the above mentioned variables, treatment with liraglutide
was entered as the independent variable at step 3. This explained an additional
2% variance in urinary albumin/creatinine ratio only, F (10, 95) =2.21,
p=0.023. In the final model baseline urinary albumin/creatinine ratio and
change in diastolic blood pressure were highly statistically significant.
Baseline urinary albumin/creatinine ratio had a higher predictive value
(β=-0.283, p=0.004) than change in diastolic blood pressure                 
(β=0.264, p=0.024). In addition the predictive value of baseline HbA1c 
(β=0.188, p=0.07) approached statistical significance. 
The biomarkers of endothelial dysfunction and inflammation in were measured
at baseline and 3 months after liraglutide therapy 9 subjects (4 males and 5
females) with type 2 diabetes and normal albumin/creatinine ratio. The results
are shown on table 4 and figure 5.
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DOMAIN
n=11
BASELINE
Mean (Standard
Deviation)
3 MONTHS AFTER
LIRAGLUTIDE
Mean (Standard
Deviation)
CHANGE AFTER 3
MONTHS
Mean (95% Confidence
intervals)
Significance.
p=
BMI
(kg/m2)
41.83 ± 7.03 40.19 ± 7.11 -0.92 (-1.63 to -0.21) 0.01
HbA1c
mmol/mol
69.70 ± 10.94 58.30 ± 11.32 -11.4 (-18.07 to -4.73) 0.00
Systolic Blood Pressure
(mmHg)
145.44 ± 21.01 137.89 ± 19.97 -7.55 (-20.99 to +5.88) 0.23
Diastolic Blood Pressure
(mmHg)
75.33 ± 10.94 73.78 ± 15.25 -1.55 (-8.36 to +5.25) 0.61
Total Cholesterol
(mmol/l)
4.45 ± 1.25 4.29 ± 1.26 -0.16 (-0.83 to +0.51) 0.6
LDL Cholesterol
(mmol/l)
2.21 ± 0.79 2.27 ± 1.05 +0.06 (-0.50 to +0.62) 0.81
Urinary
Albumin/Creatinine
(mg/mmol)
0.98 ± 0.52 0.90 ± 0.74 -0.07 (-0.79 to +0.63) 0.81
sICAM-1
(ng/ml)
1306.38 ± 729.84 1481.25 ± 572.68 +174.86 (-111.18 to
+460.91)
0.19
sVCAM-1
(ng/ml)
947.66 ± 414.53 1301.86 ± 627.43 +354.19 (+79.28 to
+629.21)
0.02
MCP-1
(pg/ml)
117.54 ± 39.28 84.03 ± 34.03 -33.50 (-77.76 to
+10.76)
0.11
hsCRP
(mg/l)
6.04 ± 3.51 4.86 ± 3.54 -1.17 (-0.48 to+2.83) 0.14
Table 4.4: CLINICAL PARAMETERS AND SERUM BIOMARKERS IN
SUBJECTS WITH NORMAL URINARY ALBUMIN/CREATININE AT
BASELINE AND 3 MONTHS AFTER TREATMENT. sICAM-1 levels
remained unchanged after 3 months of treatment. A statistically significant
increase in sVCAM-1 was noted after treatment. No changes were evident in
circulating levels of biomarkers of inflammation.
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Figure 4.5: BASELINE AND POST TREATMENT LEVELS OF
BIOMARKERS OF ENDOTHELIAL DYSFUNCTION AND
INFLAMMATION. No significant changes in circulating levels of the above
mentioned biomarkers were evident 3 months after treatment with liraglutide.
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There was a statistically significant increase in plasma sVCAM-1 in patients
with normal urinary albumin/creatinine ratio after 3 months of treatment with
liraglutide indicating progressive endothelial dysfunction. However there was
no change in serum levels of sICAM-1 pre and post treatment. MCP-1 and
hsCRP levels were unchanged after 3 months of treatment with liraglutide.
There were no statistically significant changes in blood pressure, total
cholesterol, LDL cholesterol or urinary albumin/creatinine ratios.
Discussion
In our cohort study the progression of diabetic kidney disease as evidenced by
urinary albumin creatinine ratio was not influenced by liraglutide. Our
regression model was robust as evidenced by F=2.10 which was statistically
significant with p=0.036. After controlling for the effects of age, duration of
diabetes, baseline blood pressures and baseline HbA1c, the most reliable
predictor of change in albumin excretion in our cohort was the baseline urinary
ACR. This is in agreement with previously published data on progression of
ACR in subjects with normoalbuminuria (Forsblom, Groop et al. 1998,
Poulsen, Ebbehøj et al. 1999, Yamada, Komatsu et al. 2005). Smoking and
glycaemic control have also been noted to adversely influence progression of
normoalbuminuria (Forsblom, Groop et al. 1998). In our retrospective cohort,
the data on smoking status of subjects was incomplete; hence we were not able
to confirm or refute this observation. In our study the influence of baseline
HbA1c approached statistical significance with p=0.07.
Hypertension is closely linked with development of microalbuminuria in
subjects with normal urinary ACR (1998, Adler, Stevens et al. 2003, Casas,
121
Chua et al. 2005). In our study, the regression of urinary ACR was associated
with reduction in diastolic blood pressure but no association with systolic
blood pressure was evident. Previous studies in normoalbuminuric subjects
have noted a correlation between urinary ACR and a blunted circadian
variation in blood pressure (Poulsen, Ebbehøj et al. 1999). In one study, the
nocturnal systolic blood pressure correlated with urinary ACR. But there was
no correlation between ACR and daytime blood pressure or mean blood
pressure(Lurbe, Redón et al. 1993). It is possible that subjects in our study
who had progression of urinary ACR had significant nocturnal systolic
hypertension. This could be a possible reason why the change in systolic blood
pressure (recorded during clinic visit) was not a significant predictor of
outcome in our cohort.
Our regression analysis of the data indicated that the total model was able to
explain 19% of the change in urinary ACR at 12 months. Our model based on
retrospective anthropometric and clinical biochemistry data was unable to
explain the remaining 81% of variability. This suggests that a number of other
factors that are not measured as part of routine clinical practice might be
involved in influencing development of microalbuminuria. We hypothesised
that biomarkers of endothelial dysfunction and low grade inflammation might
be predictors of disease progression.
In a previously published prospective observational study, 192 patients with
normoalbuminuria were followed up to a maximum of 9 years. It was noted
that subjects with endothelial dysfunction (indicated by raised serum sICAM-1
and aVCAM-1 levels) were more likely to have progressive diabetic renal
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disease (Astrup, Tarnow et al. 2008). It has been shown that serum levels of
MCP-1and hsCRP are closely associated with urinary albumin excretion in
patients with normoalbuminuria and type 2 diabetes (Takebayashi, Matsumoto
et al. 2006, Astrup, Tarnow et al. 2008). Animal studies have shown that
MCP-1 plays a critical role in the inflammation of the kidney leading on to
diabetic nephropathy (Chow, Nikolic-Paterson et al. 2006, Chow, Nikolic-
Paterson et al. 2007). We hypothesised that liraglutide might modulate the
above mentioned pathways, thereby influencing development of
microalbuminuria in subjects with normal urinary albumin excretion.
The results as displayed above do not show any significant change in sICAM-
1, MCP-1 or hsCRP levels after treatment with liraglutide. There was a small
but significant change in serum sVCAM-1 levels. This needs to be interpreted
with caution because of the lack of a control group in the prospective arm of
our study. The reasons why the beneficial effect noted in rat models were not
replicated in human studies are likely to be multifactorial.
In a rodent study, a radiolabelled compound specifically targeting the GLP-1
receptor was employed to image the GLP-1 receptor positive tissues in vivo. A
very high bio distribution was noted in rat kidneys, pancreas and lung. In
addition a large proportion of the ligand/receptor complex was retained in the
kidney when compared with other tissues. The investigators noted that uptake
in rat kidneys could not be specifically inhibited, indicating a mechanism that
is not saturable (Gotthardt, Lalyko et al. 2006). The GLP-1 receptor in human
kidneys is generally expressed at a low level (Körner, Stöckli et al. 2007). The
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relative abundance of the receptor might one reason why the renal effects
noted in rat models were not replicated in our human study.
Even though human and rat GLP-1 receptors are similar, there is a 10%
difference in the amino acid sequences of the protein between the two species
(Baggio and Drucker 2007). As the GLP-1 analogues are designed to work on
human GLP-1 receptor, they might interact differently with the rat GLP-1
receptor. There is also evidence that some of the effects of native GLP-1 in
rats might be due to GLP-1 receptor independent mechanisms. A study on
intact mouse blood vessels supports the existence of a vasodialatory signalling
mechanism for GLP-1 that is independent of the known functional receptor.
This vasodialatory response was thought to be mediated by a metabolite of
GLP-1 acting via nitric oxide dependent cGMP release (Ban, Noyan-Ashraf et
al. 2008). This receptor independent pathway might account for some of the
effects on the renal vasculature of rats, thereby influencing diabetic
nephropathy. Hence it is difficult to extrapolate the GLP-1 effects on rat
models of nephropathy to human subjects with diabetes.
Conclusion
In conclusion, treatment with liraglutide does not have an influence on the
development of microalbuminuria in subjects with type 2 diabetes and normal
urinary albumin/creatinine ratios. In view of the possible protective effect of
GLP-1 noted in rat models, it will be appropriate to repeat the experiments in
higher mammals. As our knowledge of biomarkers that predict progression to
microalbuminuria is incomplete, longitudinal human studies are required to
evaluate reliable markers specific to diabetic kidney disease.
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CHAPTER 5
EFFECT OF LIRAGLUTIDE ON DIABETIC
RETINOPATHY IN PATIENTS WITH TYPE 2
DIABETES
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Introduction
Diabetic retinopathy is the most severe ocular complication of diabetes and
usually manifests as gradual, painless progression of visual loss.(Coyne,
Margolis et al. 2004, Frank 2004). Out of all the complications of diabetes,
retinopathy has possibly the most substantial negative effect on activities of
daily living(Fenwick, Pesudovs et al. 2011). Although advances in the
management of diabetic retinopathy have reduced the risk of blindness, it still
remains a significant problem because diabetes is a common disease.
Randomised controlled trials have shown that maintenance of near normal
glycaemia and tight control of blood pressure contribute substantially towards
slowing the progression of diabetic retinopathy (1993, Beulens, Patel et al.
2009). Laser retinal photocoagulation introduced in the 1960s substantially
reduced the risk of severe visual impairment due to retinopathy. Pan-retinal
photocoagulation used in the ‘Diabetic Retinopathy Study’ causes regression
of new vessels in the retina without actually photocoagulating them(1981).
Presumably, hypoxia in peripheral regions of the retina acts as a stimulus for
neovascularisation, which is removed by photocoagulation. Focal laser
treatment significantly reduced the progression of visual loss due to macular
oedema in the ‘Early Treatment Diabetic Retinopathy Study’(1991). Even
though the mechanism of action of laser therapy is still hotly debated, it has
become standard treatment for advanced diabetic retinopathy.
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Increased expression of VEGF is currently thought to be the key mediator of
diabetic retinopathy. VEGFs are a family of peptides produced from a single
gene and are mitogenic for vascular endothelial cells and also increase
permeability of the microvasculature(Frank 2004). It has been shown that
hypoxia, which is a strong stimulus for neovascularisation, is associated with
increased VEGF expression(Shweiki, Itin et al. 1992). In the presence of
active neovascularisation, the levels of VEGF in vitreous humour are raised 20
times, when compared with normal eyes (Aiello, Avery et al. 1994). Anti-
VEGF treatment is the most recent advance in the management of diabetic
maculopathy and has shown promising results (Virgili, Parravano et al. 2012).
Animal studies suggest a possible protective role for GLP-1 in diabetic
retinopathy (Zhang, Wang et al. 2009, Zhang, Zhang et al. 2011). However
limited human studies suggest a possible adverse effect of GLP-1 based
treatments on progression of retinopathy(Brooks and Lissett 2009).
Aim
In this study, I have explored the effect of liraglutide on diabetic eye disease of
subjects with type 2 diabetes.
Methods
From the database of patients at University hospital of Coventry and
Warwickshire NHS trust, we identified the subjects treated with liraglutide,
who had a retinal photograph in the 6 month period before starting the drug.
From this group we identified the patients who continued liraglutide for at
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least 12 months and had a repeat retinal screening at the end of the 12 month
period. The flowchart below depicts how cases were identified.
Matched controls were identified from the DIAMOND database at the
hospital. The controls were patients with type 2 diabetes, not treated with
liraglutide and had 2 retinal photographs at least 12 months apart. The
flowchart below depicts selection of controls.
402 patients treated with liraglutide at University hospital of
Coventry and Warwickshire NHS trust
136 patients had retinal screening less than 6 months
prior to commencement of liraglutide
67 patients had all the outcome parameters
checked at baseline and at 12 months
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The retinopathy grades in both eyes of the cases and controls were collected
from the OPTOMIZE database. The changes in retinopathy grades over 12
months were compared between cases and controls.
Primary outcome
1. Changes in retinopathy grades after 12 months when compared with
baseline retinopathy grades.
2492 patients with type 2 diabetes at University hospital of
Coventry and Warwickshire NHS trust-DIAMOND database
2100 patients had regular annual retinal screening
875 patients had all the outcome variables
recorded at annually
58 patients were matched with
cases on baseline characteristics
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Secondary outcome
1. Changes in BMI, HbA1c, total cholesterol, systolic and diastolic blood
pressures of subjects after 12 months, when compared with baseline
values.
All patients attending the GLP-1 clinic to commence treatment with liraglutide
were invited to participate in the prospective study. Details of patient
recruitment are detailed in chapter 2-Methods. Out of 42 patients, 19 patients
agreed to participate. They were recruited in the prospective study after
informed consent. Fasting plasma samples were collected from the subjects
before and 3 months after treatment.
Each serum sample was assayed for the molecule of interest in duplicate and
the mean of the two values was used for statistical analysis. If the duplicates
varied by >10%, that particular sample was excluded from the analysis.
Primary outcome
1. Changes in plasma VEGF levels of subjects after 3 months of
liraglutide treatment.
Results
In our retrospective cohort study, the retinopathy grades of 133 eyes (67
patients) were compared before, and 12 months after treatment with
liraglutide. They were correlated with retinopathy grades of an appropriately
matched control group of 116 eyes (58 patients) who had 2 retinal photographs
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at least 12 months apart. The baseline characteristics of the two groups of
patients are shown on table 1.
DOMAIN LIRAGLUTIDE
Mean (Standard
deviation)
CONTROL
Mean (Standard
deviation)
Number 133 116
Males:Females (number) 63:70 53:63
Duration of diabetes (years) 11 ± (7.87) 11.81 ± (8.55)
Age (years) 56.25 ± (9.24) 58.53 ± (9.93)
Body weight (kg) 111.52 ± (18.40) 106.70 ± (19.94)
Body mass index (kg/m2) 39.04 ± (5.47) 37.95 ± (5.32)
HbA1c (mmol/mol) 69.80 ± (16.24) 68.00 ± (17.19)
Systolic blood pressure (mm
Hg)
147.81 ± (18.01) 144.06 ± (16.14)
Diastolic blood pressure (mm
Hg)
80.06 ± (9.28) 82.49 ± (10.85)
Total cholesterol (mmol/l) 4.00 ± (0.84) 4.39 ± (1.30)
Urinary albumin/creatinine
(mg/mmol)
4.59 ± (8.69) 6.76 ± (11.90)
Visual acuity (6/x) 7.23 ± (5.43) 7.97 ± (6.81)
R score (%) R0-57.9%
R1-41.4%
R2-0.8%
R0-54.3%
R1-40.5%
R2-5.2%
M score (%) M0-93.2%
M1-6.8%
M0-93.1%
M1-6.9%
Table 5.1: BASELINE CHARACTERISTICS OF SUBJECTS TREATED
WITH LIRAGLUTIDE AND MATCHED CONTROLS
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After 12 months change in the severity of retinopathy in each eye was scored
as ‘improved’, ‘stable’ or ‘worse’. Retinopathy was defined as ‘improved’ if
there was a reduction in the ‘R’ and/or ‘M’ grade. If there were no change in
both ‘R’ and ‘M’ grades after 12 months, the eye was defined as ‘stable’. If
there was an increase in the ‘R’ and /or ‘M’ grade, the eye was defined as
‘worse’. As laser therapy causes a significant change in retinopathy grades,
eyes treated with photocoagulation during the 12 month period were excluded.
Normality of distribution of the baseline variables were assessed by
Kolmogorov-Smirov and Shapiro-Wilk tests using SPSS software (threshold
for significance was 0.05). If the ‘p’ values for both tests were non-significant,
these variables were considered normally distributed for the purpose of this
study.
Chi-square test for independence indicated no significant association between
change in severity of retinopathy and treatment with liraglutide, χ2 (2, n=
249)=2.684, p=0.261, Cramer’s V=0.104. The results are shown on figure 1.
At 12 months there were significant improvements in HbA1c and BMI of
subjects treated with liraglutide as shown on figure 2. However, the changes in
blood pressure and total serum cholesterol were not significant between the
groups as shown on figure 3.
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Figure 5.1: CHANGES IN SEVERITY OF RETINOPATHY AFTER 12
MONTHS. Chi-square test for independence did not detect any statistically
significant association between change in severity of retinopathy and treatment
with liraglutide.
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Figure 5.2: CHANGES IN BMI AND HBA1C OF CASES AND
CONTROLS. Treatment with liraglutide for 12 months resulted in statistically
significant improvements in BMI and HbA1c when compared with controls.
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Figure 5.3: CHANGES IN BLOOD PRESSURE AND TOTAL SERUM
CHOLESTEROL OF CASES AND CONTROLS. No statistically significant
changes in total cholesterol levels or blood pressures were evident between the
two groups.
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We measured plasma VEGF levels of 19 patients with type 2 diabetes and
varying grades of retinopathy before and 3 months after treatment with
liraglutide. The baseline characteristics of the subjects are shown on table 2.
DOMAIN BASELINE CHARACTERISTICS
Mean (Standard deviation)
Number of eyes 19
Males:Females 9:10
Number of eyes 38
Retinopathy grades R0=22
R1=10
R2=3
R3=3
Age
(years)
56.10 ± 10.45
Duration of diabetes
(years)
9.70 ± 6086
Urinary albumin/creatinine
(mg/mmol)
4.73 ± 6.63
Body Mass Index
(kg/m2)
44.61 ± 14.00
HbA1c
(mmol/mol)
72.05 ± 18.07
Table 5.2: BASELINE CHARACTERISTICS OF SUBJECTS TREATED
WITH LIRAGLUTIDE
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When compared with baseline values, there were no significant changes in
VEGF levels of the subjects after liraglutide treatment. The results are shown
on figure 4. However significant improvements in HbA1c and BMI were
noted.
Figure 5.4: PLASMA VEGF LEVELS AT BASELINE AND 3 MONTHS
POST TREATMENT IN SUBJECTS WITH TYPE 2 DIABETES. There were
no statistically significant differences in mean circulating VEGF levels of the
study cohort after 3 months treatment with liraglutide.
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Discussion
Our study has shown that treatment with liraglutide does not have a
detrimental effect on diabetic retinopathy in subjects with type 2 diabetes.
There is a case report of rapid improvement in glycaemic control caused by
addition of GLP-1 analogue treatment resulting in worsening of diabetic
retinopathy (Brooks and Lissett 2009). A retrospective analysis of patients
treated with exenatide for at least 6 months was performed by Varadhan et al
to assess its effect on retinopathy. Subjects with one retinal photograph before
commencement of treatment and a repeat photograph taken at least 3 months
after starting exenatide were included in this study. Worsening of retinopathy
was noted in 29% patients, whereas an improvement was noted in 19%
(Varadhan, Humphreys et al. 2011). To our knowledge this is the only
published human study exploring the effect of GLP-1 analogues on
retinopathy.
As acknowledged by the authors, the results had to be interpreted with caution
because of lack of a control group. In addition the duration of follow ranged
from 90 to 617 (mean 216) days. The worsening of retinopathy was thought to
be due to rapid improvement in glycaemic control following exenatide
treatment. In the Diabetes Complications and Control Trial (DCCT), it was
noted that patients subjected to intensive insulin treatment had initial
worsening of retinopathy in the first few months followed by an improvement
(1998).
Hence, in our study we included a matched group of patients who were not
treated with liraglutide as controls. We standardised the inclusion and
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exclusion criteria with regards to the timing of retinal photography as
explained in detail in the methods section. We also specified that the second
retinal photograph should be done at least 12 months after starting liraglutide
to overcome the confounding effect of transient initial worsening of
retinopathy. In our retrospective cohort study, wherein cases and controls were
matched for baseline anthropometrics, clinical biochemistry and initial severity
of retinopathy, treatment with liraglutide did not influence the course of
diabetic retinopathy.
We performed sequential multivariate logistic regression to identify other
parameters that might have an effect on retinopathy. The change in severity of
retinopathy in each eye, scored as ‘improved’, ‘stable’ or ‘worse’ as mentioned
above was defined as the dependent variable. Age, gender and duration of
diabetes were entered as independent variables in step 1. In step 2 severity of
retinopathy at baseline was entered as initial ‘R’, ‘M’ and ‘P’ grades in each
eye. After step 2 the total model explained 16% of variability in the dependent
variable. In step 3 baseline values and the changes in HbA1c, BMI, systolic
and diastolic blood pressures were entered. After controlling for the above
mentioned variables, treatment with liraglutide was entered in the final step.
The total model was robust, as evidenced by F (16, 204)=3.035, p<0.01 and
explained 19% of variability in progression of retinopathy. Whether the patient
was treated with liraglutide or did not explain any additional variance, F
change (1, 204) = 0.729, p=0.394. In the final model, initial severity of
retinopathy as measured by ‘R’ (β=-0.33, p<0.01), ‘M’ (β=-0.25, p<0.01) and 
‘P’ (β=0.208, p=0.04) scores were statistically significant suggesting that 
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initial severity of retinopathy has the biggest influence on its further
progression or improvement.
It has been shown that baseline micro aneurysm counts can predict changes in
severity of retinopathy over the next 4 to 10 years (Klein, Meuer et al. 1995).
The epidemiology of diabetes complications study in which subjects were
followed up for 2 years also noted that initial severity of retinopathy was a
good predictor of progression (Lloyd, Klein et al. 1995). This is in agreement
with our study where the median time interval between the two retinal
photographs was 17.2 (range 13 to 21) months.
Previous studies have shown that better glycaemic control is associated with
less severe retinopathy (Brinchmann-Hansen, Dahl-Jørgensen et al. 1992,
1998, Stratton, Kohner et al. 2001, Klein, Knudtson et al. 2008). The UKPDS
is the longest intervention study to evaluate the effect of glycaemia on diabetic
retinopathy and it clearly showed that improved blood glucose control reduced
the risk of retinopathy by 25%. But the beneficial effects on retinopathy were
evident only at the 10 year follow up(1998). In the ADVANCE retinal
measurements study, 1602 patients with type 2 diabetes were followed up for
4.1 years. Intensive glycaemic control did not significantly reduce the
incidence or progression of retinopathy, but a trend towards benefit was
observed (Beulens, Patel et al. 2009). In our cohort, the change in HbA1c over
a period of 12 months did not have statistically significant effect on
progression of diabetic retinopathy; but there was a trend towards an
association between lower baseline HbA1c and improvement in severity of
retinopathy.
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In some longitudinal studies, tight blood pressure control is also associated
with better retinopathy outcomes, but the strength of association is less than
with glycaemia (Matthews, Stratton et al. 2004, Klein, Knudtson et al. 2008).
Again the association was more evident with longer duration of follow up.
Among the 1148 subjects with hypertension in the UKPDS study, good control
of blood pressure reduced the incidence and progression of retinopathy by
34%, but this effect was seen only after 7.5 years (Matthews, Stratton et al.
2004). In our regression analysis, blood pressure was not a significant
predictor of change in severity of retinopathy. This observation is likely due to
the relatively short duration of follow up in our study.
In our prospective study we measured serum VEGF as a biomarker for
retinopathy which might indicate the course of retinopathy over time. Previous
studies showed that serum and ocular VEGF levels are closely associated with
severity of diabetic retinopathy and it has been proposed that serum cytokines
such as VEGF can be used as a prognostic marker for retinopathy (Koleva-
Georgieva, Sivkova et al. 2011, Mahdy and Nada 2011). Antiangiogenic
therapy with anti-VEGF modalities is currently used as a treatment for diabetic
retinopathy (Virgili, Parravano et al. 2012). In a prospective human trial,
intravitreal injection of anti-VEGF drug bevacizumab caused a reduction in
plasma VEGF levels before a significant change in retinopathy is seen (Ma,
Zhang et al. 2012).
It is interesting to note that GLP-1 was found to be beneficial in animal models
of retinopathy. GLP-1 receptor is expressed in the retina of rats predominantly
in the inner layer. Exenatide administration has been shown to prevent retinal
cell death and maintain normal retinal thickness in a rat model of diabetic
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retinopathy (Zhang, Wang et al. 2009). Intravitreal administration of exendin-4
in rats has been shown to protect the retina, functionally and morphologically
from the insults of diabetes. The protective effect is thought to be due to up
regulation of GLP-1 receptor and excitatory amino acid transporter in the
Muller cells of the retina (Zhang, Zhang et al. 2011). GLP-1 produced by
intravitreally implanted beads improved the survival of ganglion cells in rat
retinae after an experimental optic nerve crush(Zhang, Zhang et al. 2011). To
our knowledge, human studies have not been done to evaluate the role of the
GLP-1 receptor in diabetic retinopathy.
I did not detect any significant change in serum VEGF levels of subjects with
type 2 diabetes after treatment with liraglutide, suggesting that GLP-1
analogues do not influence retinopathy in humans. This is in agreement with
the results of our retrospective cohort study.
Conclusion
Treatment with liraglutide does not have an adverse effect on progression of
diabetic retinopathy in subjects with type 2 diabetes. This is in contrast to a
previous uncontrolled study that suggested a possible detrimental effect of
exenatide on diabetic retinopathy. In animal models, GLP-1 based treatments
had a beneficial effect on retinopathy. However, in this first ever prospective
human study there was no change in blood VEGF concentrations (biomarker
for retinopathy) following treatment with liraglutide.
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CHAPTER 6
EFFECT OF LIRAGLUTIDE ON BODY COMPOSITION
AND MARKERS OF CARDIOVASCULAR RISK IN
PATIENTS WITH TYPE 2 DIABETES AND MORBID
OBESITY
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Introduction
The prevalence of obesity and type 2 diabetes are increasing globally as a
result of high calorie diets and sedentary lifestyle that have become common
in modern society (Fernández, Casazza et al. 2008). Unfortunately most
therapies targeting hyperglycaemia cause weight gain which is associated with
increased cardiovascular risk (1998, Purnell, Hokanson et al. 1998). Recently,
excess adiposity and insulin resistance have been identified as novel predictors
of cardiovascular risk independent of traditional risk factors such as BMI and
blood pressure (Haffner, Mykkänen et al. 2000, Saely, Aczel et al. 2005).
Therapies such as GLP-1 analogues that induce weight loss while improving
glycaemic control have a beneficial influence on body composition of subjects
with a mild degree of obesity.
Exenatide, the first GLP-1 analogue licenced to treat diabetes was noted to
reduce body fat mass and improve markers of cardiovascular risk in subjects
with mild obesity (Mean BMI 30 kg/m2). Short term (20-28 days) treatment
with liraglutide in human subjects with mild obesity showed conflicting effects
on body composition (Harder, Nielsen et al. 2004, Horowitz, Flint et al. 2012).
But in two randomised controlled trials lasting 26 to 52 weeks, liraglutide
induced significant reductions in total body fat and percentage of body
fat(Garber, Henry et al. 2009, Jendle, Nauck et al. 2009, Nauck, Frid et al.
2009). The average BMI of subjects in the two studies were 30 kg/m2 and 33
kg/m2 respectively. The effect of liraglutide on body composition and
cardiovascular risk markers has not been studied in subjects with morbid
obesity defined as BMI > 40 kg/m2.
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Aim
The aim of our study was to evaluate whether subjects with type 2 diabetes
and morbid obesity treated with liraglutide had a change in total and regional
adiposity. We also assessed the effect on glucose-insulin homeostasis in these
subjects as a marker of cardiovascular risk in addition to other clinical
parameters.
Methods
All subjects attending the GLP-1 clinic at University hospital of Coventry and
Warwickshire were invited to participate in this prospective study. The details
of the study were explained to the patients by the principal investigator or a
member of the research team. Patients were requested to consider participation
after reflection for at least 24 hours. Out of 43 patients, 20 subjects (10 men
and 10 women) with morbid obesity and type 2 diabetes agreed to participate.
Body composition analyses at baseline and 3 months after treatment were
performed using InBody 720 analyser as described in the methods section.
Blood tests and anthropometric data were collected at baseline and at follow
up. HOMA2 calculator software (Diabetes trials unit, University of Oxford)
was employed to calculate insulin sensitivity and beta cell function.
Each serum sample was assayed for the molecule of interest in duplicate and
the mean of the two values was used for statistical analysis. If the duplicates
varied by >10%, that particular sample was excluded from the analysis.
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Primary outcomes
1. Changes in BMI, fat mass an lean body mass after 3 months of
treatment with liraglutide
2. Changes in insulin sensitivity measured as HOMA%S
Results
The baseline and 3 month follow up data on anthropometrics and clinical
markers of cardiovascular risk are shown on table 1. The average age of
patients in our study was 56.1 years (standard deviation 10.4). All subjects
completed the three month study. Data was analysed using SPSS software
version 21. Paired samples‘t’ test was employed to compare mean changes in
continuous variables at baseline and 3 months after treatment.
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DOMAIN
n=20
BASELINE
Mean (Standard
Deviation)
3 MONTHS
AFTER
LIRAGLUTIDE
Mean (Standard
Deviation)
CHANGE AFTER 3
MONTHS
Mean (95%
Confidence
intervals)
Significance. p=
Body weight
(kg)
127.19 (41.80) 123.14 (38.07) -4.04 (-1.52 to -6.56) 0.01
Waist circumference
(cm)
125.90 (19.90) 121.14 (16.98) -4.76 (-1.99 to -7.52) 0.01
Waist:Hip ratio
(ratio)
F 0.94 (0.06)
M 1.05 (0.08)
F 0.92 (0.07)
M 1.03 (0.09)
F -0.02 (-0.01 to -
0.03) M -
0.02(-0.02 to +0.01)
0.008
0.155
Systolic blood
pressure (mm
Hg)
149.74 (19.38) 139.63 (17.56) -10.10 (-1.37 to -
18.83)
0.03
Diastolic blood
pressure (mm
Hg)
77.26 (10.61) 72.53 (13.29) -4.73 (+0.47 to -9.94) 0.07
Average insulin dose
over 24 hours (n=10)
(units)
68.52 (96.21) 40.19 (60.86) -28.33 (-2.58 to -
54.07)
0.03
HbA1c
(mmol/mol)
72.05 (18.77) 58.19 (11.74) -13.85 (-7.30 to -
20.40)
0.01
Total cholesterol
(mmol/l)
4.21 (1.02) 3.92 (1.09) -0.28 (+0.07 to -0.64) 0.11
HDL cholesterol
(mmol/l)
1.18 (0.37) 1.14 (0.26) -0.03 (+0.05 to -0.12) 0.44
LDL cholesterol
(mmol/l)
2.08 (0.65) 1.99 (0.87) -0.09 (+0.20 to -0.39) 0.51
Triglycerides
(mmol/l)
2.07 (1.15) 1.74 (0.85) -0.32 (+0.04 to -0.61) 0.03
Table 6.1: CLINICAL AND BIOCHEMICAL PARAMETERS AT
BASELINE AND 3 MONTHS AFTER TREATMENT WITH
LIRAGLUTIDE IN 20 HUMAN SUBJECTS
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A significant reduction in average BMI from 44.97 kg/m2 to 43.68 kg/m2
(mean difference 1.28 kg/m2; 95 % confidence intervals 0.26 to 2.26, p=0.013)
was seen after 3 months. A reduction in percentage of body fat from 46.60% to
45.83% (mean difference 0.77%; 95 % confidence intervals 0.25 to 1.29,
p=0.006) was also noted in these patients. These results are illustrated on chart
1.
Figure 6.1: CHANGES IN BMI AND PERCENTAGE OF BODY FAT IN
SUBJECTS TREATED WITH LIRAGLUTIDE FOR 3 MONTHS.
Statistically significant improvements were noted in BMI and estimated
percentage of body fat after 3 months of treatment with liraglutide.
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We also noted a significant reduction in the mean total fat mass of these
patients from 60.55 kg at baseline to 58.01 kg after 3 months (mean difference
2.54 kg; 95 % confidence intervals 1.27 to 3.81, p=0.001). But the change in
mean lean body mass from 63.22 kg to 62.07 kg during the same period was
not statistically significant (mean difference 1.14 kg/m2; 95 % confidence
intervals -0.63 to 2.92, p=0.192). The results are shown on chart 2.
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Figure 6.2: CHANGES IN MEAN LEAN BODY MASS AND FAT MASS IN
SUBJECTS TREATED WITH LIRAGLUTIDE FOR 3 MONTHS. The
changes in mean lean body masses were not statistically significant after 3
months of treatment with liraglutide. However significant improvements were
noted in fat mass after similar duration of treatment.
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We calculated the insulin sensitivity of the subjects using HOMA2 calculator
software obtained from the Diabetes trials unit at University of Oxford. The
improvement in mean insulin sensitivity expressed as a percentage (the output
of the model is calibrated to give normal insulin sensitivity as 100% in a
population) correlated with reduction in percentage of body fat even after
controlling for change in BMI(r=0.597, p=0.024). The results are shown on
chart 3.
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Figure 6.3: RELATION BETWEEN CHANGES IN HOMA-INSULIN
SENSITIVITY AND PERCENTAGE OF BODY FAT. A statistically
significant correlation was noted between changes in insulin sensitivity and
changes in percentage of body fat. Changes in insulin sensitivity did not
correlate with changes in BMI or changes in lean body mass.
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Discussion
This is the first study exploring the influence of liraglutide on body
composition and glucose-insulin homeostasis in subjects with morbid obesity.
Our results show that liraglutide treatment is associated with a significant
reduction in BMI, which is mainly due to reduction in fat mass. In our subjects
there was preservation of lean body mass even after significant weight loss.
Hence, we did not observe any significant change in estimated basal metabolic
rate (BMR) of our patients. It has been shown that, even in normal weight
subjects excess adiposity is linked with a raised LDL cholesterol, raised
triglycerides and low HDL cholesterol(Ito, Nakasuga et al. 2003). In a large
cross sectional study involving 3800 subjects, percentage of body fat, rather
than BMI was associated with cardiovascular risk. This association was seen
after adjusting for age, gender, lifestyle and family history of obesity(Zeng,
Dong et al. 2012). In our cohort, the improvement in percentage of body fat
was associated with changes in traditional markers of cardiovascular risk, such
as blood pressure.
In addition to changes in total body fat, we observed changes in regional fat
distribution. There was a significant reduction in waist:hip ratios (WHR) of
women after weight loss induced by liraglutide, but the change was not
statistically significant in men. A number of large studies have identified
WHR as an important predictor of cardiovascular risk (Dalton, Cameron et al.
2003, Welborn, Dhaliwal et al. 2003, Price, Uauy et al. 2006). In obese women
higher cardiovascular risk was associated with central or ‘android’ obesity
(WHR >0.86) than ‘gynoid’ obesity (WHR<0.86). Following liraglutide
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therapy, we observed a change from ‘android’ to ‘gynoid’ obesity in our
cohort, which is associated with cardiovascular benefit(Crepaldi, Belfiore et al.
1991).
We also noted an absolute reduction in abdominal fat mass as evidenced by a
statistically significant reduction in waist circumference (result shown on table
1). But the visceral fat area (VFA) measured by bio-impedance remained
unchanged after treatment with liraglutide for 3 months. The mean VFA of the
subjects was 213.52 cm2 at baseline and 212.60 cm2 after 3 months (change in
VFA -0.91, 95% confidence interval 7.06 to -8.90, p=0.81). This suggests that
change in abdominal fat in our cohort was mainly due to reduction in
subcutaneous abdominal fat, rather than visceral fat.
In a previous study, liraglutide treatment of subjects with mild degree of
obesity (BMI 30-33 kg/m2) induced a significant improvement in both visceral
and subcutaneous adipose tissues were noted (Jendle, Nauck et al. 2009). It is
possible that visceral adipose tissue in patients with morbid obesity is less
susceptible to weight loss interventions. The expression of genes related to cell
cycling, membrane transport and energy metabolism is different in the adipose
tissues of morbidly obese subjects, when compared with controls(Baranova,
Collantes et al. 2005). The reason why our subjects did not lose any significant
visceral adipose tissue could be due to inherent differences in cell turnover as a
result of morbid obesity.
Instruments such as InBody 720 that employ the technique of Bio impedance
Spectroscopy are able to provide estimation of fat mass, lean body mass,
skeletal mass and water content of inta-cellular and extra-cellular
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compartments (Heymsfield, Wang et al. 1996, Nuñez, Gallagher et al. 1997).
This technique is preferred by investigators in view of portability, ease of use,
relatively low cost, minimal participant participation and safety (Rush, Chandu
et al. 2006).
Head to head comparison studies have noted that Bio impedance techniques
provided values that compared favourably with values obtained by dilution
technique for fat mass and fat free mass (Papathakis, Rollins et al. 2005). Bio
impedance values for fat free mass were underestimated in normal weight
individuals and overestimated in overweight individuals when compared with
DEXA (Ward, Dyer et al. 2007). CT scanning, Air displacement
plethysmography and dilution techniques are less frequently used techniques
for estimation of body composition (Clasey and Gater 2005, Noreen and
Lemon 2006, MacNeil and Boyd 2007, MacNeil and Boyd 2007).
It is important to recognize that no single method of estimating body
composition can be considered as gold-standard. Repeated measurements
using the same technique over time can give valuable information over
temporal changes in a cohort (Lee and Gallagher 2008).
Changes in glucose-insulin homeostasis as assessed by HOMA were evident in
our patients and were mainly due to changes in total body fat. Matthews et al
in 1985, first described homeostatic model assessment (HOMA) of insulin
resistance and β cell function (Matthews, Hosker et al. 1985). In the basal 
state, the relationship between blood glucose and insulin reflects the balance
between hepatic glucose output and insulin secretion from the pancreatic β 
cells(Turner, Holman et al. 1979). The predictions used in HOMA are based
155
on data from experimental studies on humans. Its most recent version
HOMA2, has non-linear solutions and takes into account variations in hepatic
and peripheral glucose resistance (Rudenski, Matthews et al. 1991, Levy,
Matthews et al. 1998). The computer model can be used to determine insulin
sensitivity as %S (normal sensitivity is 100%) and β cell function as %B 
(normal β cell function is 100%) from paired fasting glucose and insulin 
measurements. This model allows for insulin sensitivity to be assessed in
individuals treated with insulin as long as the blood sampling is done when
glucose and insulin concentrations are in a steady state(Wallace, Levy et al.
2004). However the HOMA model is not suitable for assessment of β cell 
function in patients treated with exogenous insulin.
The safety and efficacy of liraglutide were assessed in the Liraglutide Effect
and Action in Diabetes (LEAD) programme that comprised of six randomised
controlled trials. These trials compared liraglutide with a range of anti-diabetic
drugs as monotherapy and combination therapy. Data from these trials have
shown conflicting effects of liraglutide on insulin resistance, in spite of
consistent improvements in BMI. A proportion of participants in LEAD-2 and
LEAD-3 trials had body composition analyses that showed significant
reduction in fat mass with liraglutide (Jendle, Nauck et al. 2009). In LEAD-3
trial, a significant improvement in insulin sensitivity was observed in the
liraglutide treated subjects, but this was not seen in the LEAD-1 and LEAD-2
trials (Garber, Henry et al. 2009, Marre, Shaw et al. 2009, Nauck, Frid et al.
2009). In LEAD-4 trial a significant improvement in insulin sensitivity was
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noted in both the liraglutide treatment group and the placebo group, but no
difference was seen between groups (Zinman, Gerich et al. 2009).
In our study the mean insulin sensitivity improved from 37.08% at baseline to
44.73%, 3 months after liraglutide treatment, but the change was not
statistically significant. The improvement in insulin sensitivity in our cohort
correlated with changes in BMI and in percentage of body fat. The correlation
with the latter was more pronounced and persisted even after statistically
controlling for changes in BMI. It is possible that a bigger cohort of patients
and/or longer follow we might observe a clear trend in insulin sensitivity.
Conclusion
Patients with type 2 diabetes are at risk of cardiovascular events, and the risk is
magnified by coexistent morbid obesity. In these subjects, treatment with
liraglutide for 3 months is associated with significant improvements in
surrogate markers of cardiovascular risk such as percentage of body fat and
waist:hip ratio. Human studies with hard cardiovascular end points are
required to further explore the effects of GLP-1 based treatments on
macrovascular disease associated with diabetes.
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CHAPTER 7
GENERAL DISCUSSION AND
CONCLUSION
158
Summary of background
Diabetes mellitus
Diabetes mellitus is an important cause of mortality and morbidity globally
due to its direct clinical sequelae and chronic complications (1998, 2000).
Type 2 diabetes is the most common form of diabetes worldwide. It is
associated with mortality due to premature cardiovascular disease and
morbidity due to blindness, amputation, and renal failure (Colberg, Sigal et al.
2010). It is clear that the prevalence of type 2 diabetes is rising globally fuelled
by population growth and ageing in addition to the increasing incidence of
obesity (Danaei, Finucane et al. 2011).
Chronic complications of diabetes
The earliest functional change in the kidney due to diabetes is the appearance
of glomerular hyper-filtration, which is followed by albuminuria. Patients with
micro albuminuria are referred to as having incipient nephropathy (Bakker
1999). In a proportion of patients structural changes in the kidney follow
leading on to progressive kidney injury (Molitch, DeFronzo et al. 2004).
Hence, it is recommended that patients with type 2 diabetes are screened for
microalbuminuria at diagnosis. Good glycaemic control and management of
hypertension are well established treatment strategies to slow the progression
of albuminuria (1998, 1998). Recent evidence suggests that low grade
inflammation and endothelial dysfunction are responsible for initiation and
progression of micro albuminuria (Furuta, Saito et al. 1993, Chow, Nikolic-
Paterson et al. 2007). Indeed, studies on animal models suggest that blocking
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certain inflammatory pathways can improve urinary albumin excretion (Chow,
Nikolic-Paterson et al. 2005). Ongoing research is focussed on drugs that can
modulate these inflammatory pathways, and thereby improve albuminuria.
The estimated crude prevalence rate of diabetic retinopathy in a population of
patients with any type of diabetes is about 40%, out of which 8% are likely to
have sight threatening retinopathy (Kempen, O'Colmain et al. 2004).
Management of diabetic retinopathy is based on achieving good glycaemic
control and treatment of hypertension (1993, 1998). Laser photocoagulation is
an established therapy for advanced diabetic retinal disease (1981, 1991). It
has been recognised that inflammatory pathways, mediated by VEGF are
implicated in the pathogenesis of retinopathy (Aiello, Avery et al. 1994).
It is well recognised that patients with type 2 diabetes are at risk of having
adverse cardiovascular events (Mokdad, Bowman et al. 2001, Cleary, Orchard
et al. 2006, Forbes and Cooper 2013). Management of type 2 diabetes not only
involves addressing hyperglycaemia, but also encompasses appropriate
therapy targeted at optimising other cardiovascular risk factors such as,
hypertension, hypercholesterolemia and hypertriglyceridemia (2012). Recently
it has been recognised that body composition, insulin resistance and body fat
distribution are equally significant markers of cardiovascular risk (Kissebah,
Vydelingum et al. 1982, Segal, Dunaif et al. 1987, Haffner, D'Agostino et al.
1999, Rewers, Zaccaro et al. 2004). Hence an ideal drug to treat diabetes
should also have a beneficial effect on these cardiovascular risk factors, in
addition to achieving glycaemic control.
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Glucagon like peptide-1
GLP-1 is a gut derived insulinotropic hormone, which is secreted in response
to hyperglycaemia and food intake (Holst and Orskov 2001). The receptor for
GLP-1 is widely distributed in the human body, hence the actions of this
hormone are not confined to the pancreatic β cell (Körner, Stöckli et al. 2007). 
Evidence form animal studies indicate that GLP-1 is anti-inflammatory and
protects against endothelial dysfunction (Arakawa, Mita et al. 2010, Koska,
Schwartz et al. 2010, Goto, Nomiyama et al. 2011). In animal models, GLP-1
and its analogues had a beneficial effect on diabetic nephropathy and diabetic
retinopathy (Moreno, Mistry et al. 2002, Zhang, Wang et al. 2009, Zhang,
Zhang et al. 2011, Hendarto, Inoguchi et al. 2012). To date, human studies
have not evaluated the effect of GLP-1 analogues on microvascular
complications of diabetes.
Liraglutide and microalbumnuria
In this retrospective cohort study, I compared a group of patients with type 2
diabetes who were treated with liraglutide for up to 12 months, with a matched
group of controls not treated with the drug. The changes in urinary albumin
excretion rates and changes in retinopathy grades between the groups were
compared, to detect whether liraglutide influences the course of microvascular
complications. This is the first human study to explore the effect of liraglutide
on microvascular complications of diabetes.
A prospective randomised controlled trial would be the ideal method to
investigate the effect of a drug. However data from well-designed
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retrospective studies can give valuable insight and provide preliminary data to
design a clinical study. A well-recognised weakness inherent to retrospective
analyses is that the data available is often incomplete. In this study, I had to
exclude about 40% of patients from the analysis because of incomplete data.
It is possible that improvement/worsening of microvascular complications are
reflected in serum biomarkers before a change in clinical parameters is
evident. Hence, I designed a prospective arm of the study to measure
biomarkers of nephropathy, retinopathy and cardiovascular risk in subjects
with type 2 diabetes before starting liraglutide. These biomarkers and clinical
parameters were measured under standard conditions 3 months after treatment
with liraglutide. A limitation of this prospective study was the lack of a
matched control group of patients who were not treated with GLP-1 analogues.
In patients with type 2 diabetes and established microalbumnuria, treatment
with liraglutide for 6-12 months did not have a significant impact on urinary
albumin excretion rate. However, patients treated with liraglutide had a
significant improvement in their HbA1c and BMI. Regression analysis
revealed that baseline urinary albumin/creatinine ratio, HbA1c, and blood
pressure were predictive of changes in urinary albumin excretion, which is in
keeping with previously published studies. As the rate of progression of
microalbumnuria is gradual, studies with a longer follow up duration might be
required to determine conclusively, whether liraglutide has an influence on
urinary albumin excretion. We intend to continue this study by following up
this cohort of patients prospectively.
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I conducted a similar retrospective analysis in patients with detectable urinary
albumin excretion, but not diagnostic of pathologic microalbumnuria (as
defined by the NICE criteria). The changes in urinary albumin excretion rated
were not different between the cohort of patients treated with liraglutide and
matched control subjects. As the initial urinary albumin/creatinine ratio was
low, it is possible that the subsequent change after 12 months was not large
enough to be detectable.
In a prospective study, I compared serum concentrations of the biomarkers of
inflammation (MCP-1 and hsCRP) and endothelial dysfunction (sICAM-1 and
sVCAM-1) that are closely associated with development and progression of
diabetic nephropathy in subjects before and 3 months after treatment with
liraglutide. Liraglutide therapy did not induce any change in these biomarkers.
Although, I did not show any change in biomarkers in this human study, a
number of studies in rodents have shown significant improvements in these
biomarkers and urinary albumin excretion following administration of
liraglutide (Moreno, Mistry et al. 2002, Kodera, Shikata et al. 2011, Hendarto,
Inoguchi et al. 2012).
The expression of GLP-1 receptor in human kidneys is lower than the
expression in renal tissues of rodents, which could explain the above noted
results (Körner, Stöckli et al. 2007). Another possible reason could be the
differing affinities of liraglutide to the GLP-1 receptor in humans and rodents
due to the 10% differences in the amino acid sequences between the two
species (Baggio and Drucker 2007).
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Liraglutide and diabetic retinopathy
In this retrospective study, treatment with liraglutide for 12 months did not
induce any significant changes in the retinopathy grades of patients after
controlling for other known factors that influence the course of diabetic
retinopathy. A previous retrospective audit raised concerns about risk of
progression of retinopathy following treatment with the GLP-1 analogue,
exenatide (Varadhan, Humphreys et al. 2011). However these results have to
be interpreted with caution, as the study did not include a group of patients not
treated with exenatide to act as control subjects.
In my study, the group of patients treated with liraglutide had a significant
reduction their mean HbA1c levels, but no improvements in the retinopathy
grades were evident. However a trend towards an association between lower
baseline HbA1c and improvement in retinopathy grades was noted. As noted
in the UKPDS study and confirmed by other studies, the improvement in
retinopathy lags behind the improvement in HbA1c by at least 4 years (1998,
Matthews, Stratton et al. 2004, Beulens, Patel et al. 2009). It is possible that if
the cohorts of patients in my study are followed up prospectively, more
information might be available about the effects of glycaemic control and
GLP-1 analogue treatment on retinopathy.
Studies conducted on rodents showed an improvement in diabetic retinopathy
following treatment with GLP-1 analogues (Zhang, Wang et al. 2009, Zhang,
Zhang et al. 2011). We conducted the first prospective human study involving
20 subjects with type 2 diabetes and varying degrees of retinopathy grades to
evaluate the effect of liraglutide on retinopathy. There were no significant
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changes in the circulating concentrations of VEGF, which is a surrogate
marker for the severity of diabetic retinopathy.
Influence of liraglutide on body composition
As the effects of liraglutide on body composition and insulin sensitivity have
not been explored in subjects with morbid obesity (who are group of patients
with the highest cardiovascular risk), I conducted a prospective study
involving 20 patients with type 2 diabetes and morbid obesity. After 3 months
of treatment with liraglutide, significant reductions in total body fat mass and
abdominal fat were noted, without any significant change in lean body mass.
The decline in abdominal fat was mainly due to changes in abdominal
subcutaneous fat, with little change in visceral fat (as estimated by bio-
impedance). In a study involving subjects with a mild degree of obesity,
significant improvements in both subcutaneous and visceral fat were noted
after treatment with liraglutide (Jendle, Nauck et al. 2009). It is possible that
visceral adipose tissue in subjects with morbid obesity is more ‘resistant’ to
the weight reducing effects of liraglutide. It will be interesting to see the
changes in visceral fat areas of subjects treated with liraglutide for 6 and 12
months.
The mean insulin sensitivity of this cohort of patients showed an improvement
following liraglutide treatment; however this failed to reach statistical
significance. In spite of consistent improvements in BMI following treatment
with liraglutide, the effects on insulin sensitivity have been inconsistent in
various trials (Garber, Henry et al. 2009, Jendle, Nauck et al. 2009, Marre,
Shaw et al. 2009, Zinman, Gerich et al. 2009).
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Confounding factors and limitations of the studies
1. In the retrospective cohort study, matching of the cohorts was done at
baseline. The group of patients treated with GLP-1 analogues had
statistically significant improvements in HbA1c and BMI, when
compared to the controls. This might have influenced the course of
microvascular complications and cardiovascular risk.
2. About 40% of potentially eligible subjects were excluded from the
study during the screening process due to incomplete datasets. This
might have influenced the outcome. This drawback is inherent to all
retrospective studies.
3. There was no control group for the prospective biomarker study.
4. All subjects included (cases and controls) had clinically significant
obesity with BMI >35 kg/m2. Therefore the results may not be
generalizable to subjects without obesity
Future research
It remains possible that there might be subtle effects of liraglutide on
microvascular complications, which were not evident in this study. To answer
this question conclusively, longer term prospective studies are needed.
It is planned that our cohort of subjects on liraglutide will be followed up
prospectively, as well as the controls. Data on all the above mentioned
parameters will be collected at 6 monthly intervals and similar analyses done
at 6 monthly intervals. If significant differences are noted in the rates of
progression of urinary albumin/creatinine ratio and/or retinopathy are noted,
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the next step will be to design a prospective randomised multicentre study to
further clarify the role of GLP-1 analogues in diabetes complications.
Currently it is not possible to do power calculations to design a prospective
study because we were not able to identify any significant differences between
out treatment and control groups. However, we expect further data which
might be available on continued follow up of our cohort to guide us in making
power calculations.
Conclusion
In patients with type 2 diabetes and morbid obesity, treatment with the GLP-1
analogue, liraglutide induces a significant reduction in total body fat, without
changing lean body mass. This was associated with improvements in markers
of cardiovascular risk and a trend towards enhanced insulin sensitivity.
In study on human subjects with type 2 diabetes, treatment with the GLP-1
analogue liraglutide did not influence the onset/progression of
microalbuminuria. The course of diabetic retinopathy in patients with type 2
diabetes was not influenced by treatment with liraglutide.
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